A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  1 o f  47   
  
 
P ro toco l  T i t le  Abso rp t ion  and  Sa fe t y  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ 
E va lua t ion  (ASSURE )  S tudy  in  Pa t ien t s  W i th  Cy s t i c  F ib ros i s  
Rece i v ing  En te ra l  Feed ing  
 
 
P ro toco l  Numbe r  0000498  
Ind i ca t ion  E xoc r ine  Panc rea t i c  Insu f f i c ienc y  
Da te  o f  P ro toco l  07  Ma r ch  201 6 
Re v i s ion  Da te  NA  
Sponso r  A l c res ta  Pha rmaceu t i ca l s ,  Inc .  
One  New ton  E xecu t i ve  Pa r k ,  Su i te  100  
New ton ,  MA  [ZIP_CODE]  
 
Ema i l :   
Phone :   
 
Th i s  do cumen t  con ta in s  in fo rma t ion  tha t  i s  con f iden t ia l  and  p rop r ie ta ry  to  A l c res ta  Pha rma ceu t i ca l s ,  
In c . ( “A l c res ta ” ) .  Th i s  in fo rma t ion  mu s t  be  t rea ted  by  [CONTACT_10825]  a s  con f iden t i a l  and  i s  be ing  p rov ided  fo r  the  
so le  pu rpose  o f  you r  pa r t i c ipa t ion  in  condu c t ing  a  resea rch  s tudy  w i th  Re l i zo rb TM  immob i l i zed  l ipase  
( iL ipase TM )  ca r t r idge ,  a l so  know  as  the  en te ra l  feed ing  in-l ine  ca r t r idge  ( EF IC ).  Th i s  in fo rma t ion  may  
no t  be  u sed  fo r  an y  o the r  pu rpose  and  may  no t  be  d i s c losed  to  th i rd  pa r t ies  ex cep t  as  p rov ided  
be low .  Con ten ts  o f  th i s  p ro to co l  may  be  d i s c losed  to  s tudy  pe rsonne l  unde r  you r  supe rv is ion  who  
need  to  know  the  con ten ts  fo r  th i s  pu rp ose ,  to  the  I n s t i tu t iona l  Rev iew  Boa rd  o r  Independen t  E th i cs  
Comm i t tee  sub je c t  to  the  fo l low ing :  the  con ten ts  o f  th i s  p ro to co l  ma y  no t  be  u sed  fo r  an y  o the r  
resea r ch  s tudy  and  ma y  no t  be  d i s c losed  to  an y  o the r  pe rson  o r  en t i ty  w i thou t  the  p r io r  w r i t ten  
pe rm i ss ion  o f  A l c res ta .  Th i s  does  no t  app l y  to  d i s c losu re  requ i red  by  [CONTACT_301842] l  regu la to ry  o r  
laws .  Howeve r ,  p romp t  no t i ce  mu s t  be  g i ven  to  A l c res ta  o f  an y  su ch  d i s c losu re .  Supp lemen ta l  
in fo rma t ion  and  amendmen ts  tha t  m a y  be  added  to  th i s  do cumen t  a re  a l so  con f iden t ia l  and  
p rop r ie ta ry  to  A l c res ta  and  sub je c t  to  the  same  con s ide ra t ion s  as  des c r ibed  he re in . 
  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  2 o f  47     
PROTOCOL  AGREEMENT  
P ro toco l  T i t le  Abso rp t ion  and  Sa fe t y  w i th  Sus ta ined  Use  o f  Re l i zo rb ™  
E va lua t ion  (ASSURE )  S tudy  in  Pa t ien t s  W i th  Cy s t i c  F ib ros i s  
Rece i v ing  En te ra l  Feed ing  
P ro toco l  Numbe r  0000498  
Inves t iga t iona l  
Dev ice  Re l i zo rb ™ immob i l i zed  l ipase  ( iL ipase TM )  ca r t r idge  
Ind ica t ion  E xoc r ine  Panc rea t i c  Insu f f i c ienc y  
P ro toco l  Da te  [ADDRESS_368807] ing  resea r ch  s tud ies  du r ing  and  a f te r  s tudy  comp le t ion .  
P r inc ipa l  Inves t iga to r  ________________________________________  
P r in ted  Name  ________________________________________  
S igna tu re  ________________________________________  
Da te  (ddmmm y y y y )  ________________________________________  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  3 o f  47  STUDY  SYNOPS IS  
T i t le  Abso rp t ion  and  Sa fe ty  w i th  Su s ta ined  Use  o f  R e l izo rb ™ E va lua t ion  
(ASSURE )  S tudy  in  Pa t ien t s  W i th  Cy s t ic  F ib ro s is  Rece iv ing  En te ra l  
Feed ing  
Sponso r  A lc re s ta  Pha rma ceu t ica ls ,  In c . ,  One  N ew ton  E xe cu t ive  Pa rk ,  Su i te  100 ,  
New ton ,  MA  [ZIP_CODE]  
Sponso r  
Con tac ts  Name  T i t le  Phone  
 Ch ie f  Med ica l  
O f f ice r   
 D i r e c to r ,  C l in ica l  
Ope ra t ion s   
Inves t iga t iona l  
Dev ice  
Backg round  The  R e l izo rb ™  d ige s t ive  en zyme  ca r t r idge  is  a  s ing le -u se ,  po in t -o f -ca re  
de v ice  tha t  conne c t s  in -l ine  w i th  e x is t ing  en te ra l  pump  feed  se t s  and  
pump  e x ten s ion  se t s .  R e l izo rb  is  de s igned  to  hyd ro ly ze  fa t s  con ta ined  in  
the  en te ra l  fo rmu la s ,  m im ic k ing  the  fun c t ion  o f  the  d ige s t ive  en zyme  
l ipa se  tha t  is  no rma l ly  se c re ted  by  [CONTACT_301843] c rea s .  By  [CONTACT_301844] z ing  fa t s  f rom  
en te ra l  fo rmu la ,  R e l izo rb  a l lows  fo r  the  de l ive ry  o f  abso rbab le  fa t t y  a c id s  
and  monog ly ce r ide s  fo r  pa t ien t s  who  re ce ive  en te ra l  nu t r i t ion  and  canno t  
h yd ro ly ze  fa t s  n o rma l ly .   
 
The  a c t ive  componen t  in  R e l izo rb  is  the  d ige s t ive  enz yme  l ipa se ,  wh ich  is  
co va len t ly  a t ta ched  to  po lyme r ic  bead s ;  the  l ipa se -bead  comp le x  is  ca l led  
iL ipa se TM .  A s  the  en te ra l  fo rmu la  pa s se s  th rough  R e l izo rb  du r ing  a  tube  
feed ing ,  i t  ma ke s  con ta c t  w i th  the  iL ipa se  and  the  fa t  in  the  fo rmu la  is  
h yd ro ly zed  in to  i t s  abso rbab le  fo rms  ( fa t t y  a c id s  and  monog ly ce r ide s )  
p r io r  to  inge s t ion .  The  iL ipa se  rema in s  in  the  ca r t r idge  and  is  no t  
inge s ted .  
Ind ica t ion  and  
C lass i f ica t ion  The  p ropo sed  ind ica t ion  is  fo r  u se  in  ch i ld ren  and  adu l t s  to  hyd ro ly ze  fa t s  
in  en te ra l  fo rmu la .  
The  l ipa se  u sed  in  R e l izo rb  is  de s igna ted  by  [CONTACT_301845]  D rug  
Adm in is t ra t ion  (FDA )  a s  gene ra l ly  re cogn ized  a s  sa fe  (GRAS  000216 ) .  
The  FDA  Cen te r  fo r  Food  S c ien ce  and  App l ied  Nu t r i t io n (CFSAN )  
c lea red  iL ipa se  a s  a  Food  Con ta c t  Subs tan ce  unde r  the  Food  Con ta c t  
No t i f ica t ion  p ro ce s s  on  Janua ry  20 ,  2015  (FCN  1498 ) .  REL IZORB  wa s  
c lea red  by  [CONTACT_301846] r  fo r  De v ice s  and  Rad io log ica l  Hea l th  (CDRH )  
a s  a  C la s s  I I  low -r is k  de v ice  th rough  a  de  no vo  app l ica t ion  on  No vembe r  
20 ,  2015  (DEN150001 )  and  is  ind ica ted  fo r  u se  in  adu l t s  to  hyd ro ly ze  fa t s  
in  en te ra l  fo rmu la .   
Numbe r  o f  
Pa t ien ts  App ro x ima te ly  35  ma le  and  fema le  pa t ien t s  w i th  cy s t ic  f ib ro s is  (CF )  and  
e xo c r ine  pan c rea t ic  in su f f ic ien c y  (EP I )  wi l l  be  en ro l led  in  P ro to co l  
0000498  w i th  the  in ten t ion  o f  ob ta in ing  a t  lea s t  30  e va luab le  sub je c t s  
who  comp le te  the  s tudy .  Sub je c t s  mu s t  be  ≥4  yea rs  o f  age ,  w i th  no  uppe r  
age  l im i t .  S in ce  the  in c lu s ion /e x c lu s ion  c r i te r ia  fo r  th is  s tudy  is  s im i la r  to  
P ro to c o l  0000497 ,  pa t ien t s  who  pa r t ic ipa ted  in  P ro to co l  0000497  w i l l  be  
e l ig ib le  to  pa r t ic ipa te  in  th is  s tudy  a f te r  they  ha ve  comp le ted  pa r t ic ipa t ion  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  4 o f  47  in  P ro to co l  0000497 .  
S i tes  App ro x ima te ly  10  s i te s  in  the  Un i ted  S ta te s  w i l l  pa r t ic ipa te  in  th is  s tudy .  
S i te s  tha t  a re  a c t ive ly  en ro l l ing  pa t ien t s  fo r  P ro to co l  0000497  w i l l  
p re fe ren t ia l ly  pa r t ic ipa te  in  th is  s tudy .    
Ob jec t ive  The  o ve ra l l  ob je c t ive  o f  the  s tudy  is  to  a s se s s  sa fe ty  and  to le rab i l i t y  and  
demon s t ra te  imp ro ved  fa t  abso rp t ion  w i th  su s ta ined  u se  o f  R e l i zo rb  in  
pa t ien t s  w i th  CF  who  ha ve  EP I  and  a re  re ce iv ing  en te ra l  nu t r i t ion  a s  pa r t  
o f  the i r  to ta l  nu t r i t iona l  the rapy .   In  th is  s tudy ,  sub jec t s  w i l l  be  re ce iv ing  a  
sem i -e lemen ta l  fo rmu la  con ta in ing  p re -h yd ro ly zed  p ro te in  tha t  ha s  a  h igh  
con ten t  o f  long  cha in  t r ig ly ce r ide s  ( Impa c t ® Pep t ide  1 .5 )  and  w i l l  be  u s ing  
Re l izo rb  du r ing  the i r  en te ra l  feed ing  in  p la ce  o f  o the r  the rap ie s  cu r ren t ly  
u sed  to  a id  in  fa t  d ige s t ion  and  abso rp t ion ,  su ch  as  pan c rea t ic  en zyme  
rep la cemen t  the rapy  (PERT ) .   P la sma  con cen t ra t ion  o f  long -cha in  
po l yun sa tu ra ted  fa t ty  a c id s (LCPUFA s )  su ch  a s  do co sahe xaeno ic  a c id  
(DHA ;  C :22 :6n -3 )  and  eico sapen taeno ic  a c id  (EPA ;  C20 :5n -3 )  w i l l  be  
mea su red  a s  b ioma rke r s o f  fa t  abso rp t ion .  T is sue  ac c re t ion  o f  LCPUFA s  
a s se s sed  th rough  mea su remen t  o f  e ry th ro cy te  memb rane  con cen t ra t ion s  
o f  LCPUFA s  su ch  a s  DHA  and  EPA ,  a s  we l l  a s  de te rm ina t ion  o f  the  
p ro f i le  o f  fa t t y  a c id s  in  p la sma  w i l l  a lso  be  e va lua ted  a s  add i t iona l  
b ioma rke rs  o f  fa t  abso rp t ion .  P la sma  fa t -so lub le  v i tam in  and  se rum  
p ro te in  con cen t ra t ion s  w i l l  a lso  be  mea su red  a s  ind ica to rs  o f  
e f fe c t i vene s s .  A l l  fa t ty  a c id ,  fa t -so lub le  v i tam in ,  and  p ro te in  
con cen t ra t ion s  w i l l  be  a s se s sed  in  re la t ion  to  va lue s  ob ta ined  a t  the  
beg inn ing  o f  the  run -in  pe r iod  (Day  -7 ) ,  a t  ba se l ine  (Da y  0 ) ,  and  du r ing  
Re l izo rb  u se  (Day s  30 ,  60 ,  and  90 ) .  Sa fe ty  and  to le rab i l i t y  o f  su s ta ined  
u se  o f  R e l izo rb  w i l l  be  a s se s sed  du r ing  u se  and  compa red  w i th  
ga s t ro in te s t ina l  symp toms  re co rded  du r ing  the  obse rva t ion  pha se  o f  the  
s tudy  (Day  -14  th rough  Day  -7) .   
E f f icacy   
• E va lua te  e f fe c t  o f  su s ta ined  R e l izo rb  u se  du r ing  en te ra l  feed ings  on  fa t  
abso rp t ion  th rough  se r ia l  mea su remen t s  o f  p la sma  and  t is sue  
(e ry th ro cy te  memb rane )  con cen t ra t ion s  o f  phy s io log ica l ly  re le van t  
LCPUFA s su ch  a s  DHA  &  EPA  a s  we l l  a s  se r ia l  de te rm ina t ion s  o f  the  
p la sma  fa t t y  a c id  p ro f i le  change s  a s  b ioma rke rs  o f  fa t  abso rp t ion  
• E va lua te  e f fe c t  o f  su s ta ined  R e l izo rb  u se  du r ing  en te ra l  feed ings  on  
p la s ma  fa t -so lub le  v i tam in  con cen t ra t ion s   
• E va lua te  e f fe c t  o f  su s ta ined  Re l izo rb  u se  on  the  ra t io  o f  omega -6  to  
omega -3  fa t t y  a c id s  a s  a  po ten t ia l  ind ica to r  o f  immunomodu la t ion  
• E va lua te  e f fe c t  o f  su s ta ined  Re l izo rb  u se  on  u r ina ry  leu ko t r iene  le ve ls  
• E va lua te  e f fe c t  o f  su s ta ined  Re l izo rb  u se  on  se rum  p ro te in  le ve ls  
• E va lua te  e f fe c t  o f  su s ta ined  Re l izo rb  u se  on  g row th  
Sa fe ty  
• E va lua te  the  sa fe t y  and  to le rab i l i t y  o f  su s ta ined  u se  o f  Re l izo rb  a s  pa r t  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  5 o f  47  o f  an  en te ra l  feed ing  reg imen .   
Endpo in ts  E f f icacy  
• Change  o ve r  t ime  in  p la sma  con cen t ra t ion s  o f  omega -3  fa t ty  a c id s 
su ch  a s  DHA  and  EPA   
• Change  o ve r  t ime  in  t is sue  ( e ry th ro cy te  memb rane ) fa t t y  a c id  
con cen t ra t ion s  su ch  a s  DHA  and  EPA  
• Change  o ve r  t ime  in  the  p la sma  fa t ty  a c id  p ro f i le  
• Change  o ve r  t ime  in  the  ra t io  o f  omega -6  to  omega -3  fa t ty  a c id s  
• Change  o ve r  t ime  in  p la sma  con cen t ra t ion s  o f  f a t  so lub le  v i tam in s  A ,  
D ,  and  E  
• Change  o ve r  t ime  in  se rum  p ro te in  con cen t ra t ion s  ( to ta l  p ro te in ,  
p rea lbum in ,  a lbum in ,  t ran s fe r r in )  
• Change  o ve r  t ime  in  ma rke rs  o f  in f lamma t ion  (u r ina ry  leu ko t r iene s )  
• Change  o ve r  t ime  in  we igh t  and  body  ma s s  inde x  (B M I )  and  w e igh t  
and  BM I  z -s co re s  
 
Sa fe ty  
• Frequen cy  and  se ve r i ty  o f  ad ve rse  e ven t s  and  unan t ic ipa ted  ad ve rse  
de v ice  e f fe c t s (UADE s) 
• E va lua t ion  o f  c l in ica l  and  labo ra to ry  f ind ings   
• Con com i tan t  med ica t ion  a s se s smen t  
• F requen cy  and  se ve r i ty  o f  ga s t ro in te s t ina l  s igns  and  symp toms  
(abdom ina l  pa in ,  vom i t ing ,  lo s s  o f  appe t i te , b loa t ing ,  f la tu len ce  and  
s tea to r rhea )  
S tudy  Du ra t ion  The  du ra t ion  o f  the  s tudy  is  app ro x ima te ly  7-8  mon th s .  Th ree  and  a  ha l f  
mon th s  w i l l  be  a l lo ca ted  fo r  pa t ien t  en ro l lmen t .  Pa t ien t  t ime  in  s tudy  w i l l  
be  a t  lea s t  th ree  and  a  ha l f  mon th s  (1  wee k  obse rva t ion  pe r iod ,  1  wee k  
run  in ,  3  mon th s  t rea tmen t ) , and  UADE s  tha t  o c cu r  towa rd s  the  end  o f  
the  s tudy  ma y  requ i re  ano the r  30  day s  o f  fo l low  up .    
S tudy  Des ign   P ro to co l  0000498  is  a  mu l t icen te r  open  labe l  s tudy  to  e va lua te  the  e f fe c t  
o f  su s ta ined  R e l izo rb  u se  du r ing  en te ra l  feed ing  on  fa t  abso rp t ion ,  a s  we l l  
a s  sa fe ty  and  to le rab i l i t y  o f  su s ta ined  R e l izo rb  u se ,  in  pa t ien t s  w i th  CF  
and  EP I  who  a re  re ce iv ing  en te ra l  tube  feed ing .   
A t  s tudy  en t ry  (Day  -14 ) ,  b l ood  and  u r ine  w i l l  be  co l le c ted  a s  pa r t  o f  the  
s c reen ing  e va lua t ion  and  to  a s se s s  ba se l ine  p la sma  and  e ry th ro cy te  
memb rane  con cen t ra t ion s  o f  LCPUFA s  su ch  a s  DHA  and  EPA ,  p la sma  
con cen t ra t ion s  o f  o the r  long  cha in  fa t ty  a c id s ,  p la sma  con cen t ra t ion s  o f  
fa t -so lub le  v i tam in s ,  se rum  p ro te in  con cen t ra t ion s ,  and  u r ina ry  
leu ko t r iene  con cen t ra t ion s .  Body  we igh t ,  he igh t ,  and  BM I  w i l l  be  
re co rded ,  a s  we l l  a s  h is to r ica l  quan t i f ica t ion  o f  u se  o f  PERT  w i th  da y t ime  
mea ls  and  w i th  en te ra l  feed ing .  Du r ing  an  in i t ia l  [ADDRESS_368808]  ga s t ro in te s t i na l  s ymp toms  du r ing  the  obse rva t ion  wee k  in  a  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  6 o f  47  ga s t ro in te s t ina l  symp tom  d ia ry .  Du r ing  a  7 -day  run  in  pe r iod  Day  -7  to  
Da y  -1 ) ,  sub je c t s  w i l l  u se  a  s tanda rd  en te ra l  fo rmu la  tha t  con ta in s  a  
p reh yd ro ly zed  p ro te in  (Pep tamen ® 1 .5 )  a t  the i r  no rma l  vo lume  o f  
adm in is t ra t ion  f rom  [ADDRESS_368809]  u se  o f  PERT  w i th  da i ly  mea ls  
and  sna c k s  w i l l  con t inue .   
Fo l low ing  the  run  in  pe r iod ,  sub je c t s  w i l l  re ce i ve  an  en te ra l  fo rmu la  
s im i la r  to  Pep tamen  1 .5  tha t  ha s  a  h ighe r  long  cha in  t r ig ly ce r ide  to  
med ium  cha in  t r ig ly ce r ide  ra t io  (Impa c t ® Pep t ide  1 .5 ) a t  the i r  no rma l  
vo lume  o f  adm in is t ra t ion  f rom  [ADDRESS_368810]  u se  o f  
o ra l  PERT  is  a l l owed  w i t h  da i ly  mea ls ,  bu t  u se  o f  the rapeu t ic  agen t s  
cu r ren t ly  u sed  to  a id  in  fa t  abso rp t ion ,  su ch  a s  PERT ,  w i l l  no t  be  u sed  
w i th  Re l izo rb  du r ing  en te ra l  feed ings .   
Se r ia l  mea su remen t s  (Day s  0 ,  30 ,  60 ,  and  90 )  o f  p la sma  con cen t ra t ion s  
and  e ry th ro cy te  le ve ls  o f  LCPUFA s  su ch  a s  DHA  and  EPA ,  p la sma  
con cen t ra t ion s  o f  o the r  long  cha in  fa t ty  a c id s ,  p la sma  con cen t ra t ion s  o f  
fa t  so lub le  v i tam in s ,  se rum  p ro te in  and  con cen t ra t ion s ,  u r ina ry  
leu ko t r iene  con cen t ra t ion s ,  and  body  we igh t  and  BM I  w i l l  be  ob ta ined  
and  compa red  w i th  ea ch  o the r  a s  we l l  a s  w i th  va lue s  ob ta ined  a t  s tudy  
en t ry  (Day  -14 ) .   
Sa fe ty  and  to le rab i l i t y  w i l l  be  a s se s sed  u s ing  a  ga s t ro in te s t ina l  symp tom  
d ia ry ,  a s  we l l  a s  re co rd ing  ad ve rse  e ven t s  (AE s ) ,  and  unan t ic ipa ted  
ad ve rse  de v ice  e f fe c t s  (UADE s ) .  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  
En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  7 o f  47  STUDY  SCHEMAT IC  
Tab le  1:  Schedu le  o f  Even ts  
 
Eva lu a t ion  V i s i t  1  V i s i t  2  V i s i t  3  V i s i t  4   V i s i t  5  * 
Day  -14  
S tud y  En t r y  Day  0  
Ba se l ine  Day  30  
T rea tmen t  Day  60  
T rea tmen t  Day  90  
End  o f  S tud y  
In fo rmed  Con sen t  X     
In c lu s ion  /  Ex c lu s ion  C r i te r ia  X     
Demog raph i c s  X     
Med i ca l  H i s to ry  a X     
Ph y s i ca l  Exam ina t ion  X    X   
He igh t ,  We igh t ,  Body  Ma s s  Index  b X   X X X X   
V i ta l  S ign s  c X X X X X 
Hema to log y  d X    X 
C l in i ca l  Chem i s t ry  e X    X 
U r ina l y s i s  f X    X 
B lood  L ip id s  g   X X X X X 
Se rum  P ro te in s h  X X X X X 
Se rum  P regnan cy  Te s t  (β -hCG )  i X     
U r ina ry  Leu ko t r iene s  X X X X X 
7-Da y  Ga s t ro in te s t ina l  Symp tom  D ia r y   X X X X X 
P la sma  Fa t t y  A c id  Samp le s  j X X X X X 
V i tam in s  A ,  D ,  and  Ek X X X X X 
Pep tamen ® 1 .5  500  to  1000  mL l X     
Impa c t ® Pep t ide  500  to  1000  mL   X X X X 
Re l i zo rb  Adm in i s t ra t ion    X   
Re l i zo rb  A c coun tab i l i ty  Log   X 
Unan t i c ipa ted  Adve r se  Dev i ce  E f fe c t s   X 
 
No te :   Tes ts  and  p ro cedu res  shou ld  be  pe r fo rmed  a c co rd ing  to  the  above  s chedu le  bu t  changes  in  s chedu led  s tudy  v is i ts  (± 4 day s )  a re  a l lowed  
w i th  pe rm i ss ion  f rom  the  s i te  fo r  ho l iday s ,  va ca t ion s ,  e t c . The  amoun t  o f  b lood  ta ken  f rom  sub je c t s  w i l l  be  l im i ted  to  no  mo re  than  3  mL / kg  in  
24  hou rs  and  no  mo re  than  7  mL / kg  ove r  the  cou rse  o f  the  s tudy . 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  
En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  8 o f  47  * I f  an y  Unan t ic ipa ted  Ad ve rse  De v ice  E ven t  (UADE )  is  repo r ted  on  Day  [ADDRESS_368811] . 
c .  Vi ta l  s ign s  w i l l  in c lude  b lood  p re s su re ,  pu lse  ra te ,  resp i ra to ry  ra te  and  o ra l / tympan ic  tempe ra tu re  and  w i l l  be  ob ta ined  on  in -c l in ic  
day s .  
d .  Hema to logy  in c lude s  comp le te  b lood  coun t  and  wh i te  b lood  ce l l  d i f fe ren t ia l .  
e .  C l in ica l  chem is t ry  in c lude s  a lbum in ,  a lka l ine  pho spha ta se ,  a lan ine  am ino t ran s fe ra se  (ALT ) ,  a spa r ta te  am ino t ran s fe ra se  (AST ) ,  
b ica rbona te ,  b lood  u rea  n i t rogen ,  ca lc ium ,  ch lo r ide ,  cho le s te ro l ,  c rea t ine  pho spho k ina se ,  c rea t in ine ,  g lu co se ,  la c ta te  
dehyd rogena se ,  magne s ium ,  pho spho ru s ,  po ta s s ium ,  p rea lbum i n ,  sod ium ,  to ta l  and  d i re c t  b i l i rub in ,  to ta l  p ro te in ,  u r ic  a c id  and  
A1C  le ve ls .  
f .  U r ina ly s is  to  in c lude  b i l i rub in ,  b lood ,  g lu co se ,  ke tones ,  leu ko cy te  e s te ra se ,  pH ,  p ro te in ,  spe c i f ic  g ra v i t y ,  u r ina ry  c rea t in ine  and  u r ic  
a c id . 
g .  B lood  l ip id s  w i l l  in c lude  to ta l  c ho le s te ro l ,  t r ig ly ce r ides  (TG ) ,  h igh -den s i ty  l ipop ro te in  (HDL )  and  low -den s i t y  l ip op ro te in  (LDL ) .   
h .  Se rum  p ro te in s  in c lude  to ta l  p ro te in ,  p rea lbum in ,  a lbum in ,  and  t ran s fe r r in . 
i .  A  se rum  Be ta -Human  Cho r ion ic  Gonad o t rop in  (β -hCG )  p regnan cy  te s t  w i l l  be  pe r fo rme d  on ly  fo r  fema le s  o f  ch i ldbea r ing  po ten t ia l .  
Re su l t s  mu s t  be  a va i lab le  p r io r  to  Day  1 .  
j .  Blo od  samp le s w i l l  be  ob ta ined  fo r  p la sma  and  red  b lood  ce l l  fa t ty  a c id  ana ly s is . 
k .  Blood  samp le s w i l l  be  co l le c ted  to  mea su re  le ve ls  o f  V i tam in s  A ,  D ,  and  E .  
l .  Pep tamen  1 .5  w i l l  be  adm in is te red  a s  the  en te ra l  fo rmu la  du r ing  the  run  in  pha se  f rom  Da y  -7  th rough  Da y  -1 .  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368812] IVES  AND  ENDPO INT S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21  
 Ob je c t i v e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
 Endpo in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
4 .0  STUDY  DE S IGN  AND  PROCEDURES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22  
 En ro l lm en t  Go a l s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 2  
 R ep r e s en ta t i v e  Ag e  G ro up s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 2  
 S tud y  Du r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
 S tud y  Pe r iod s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 3  
 S e l e c t ion  o f  P a t i en t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
 In c lu s ion  C r i t e r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 5  
 E x c lu s ion  C r i t e r ia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
 P a t i en t  En ro l lm en t  and  Rep l a cem en t  C r i t e r i a  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
 A l low ed  Con com i t an t  Med i c a t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
 P roh ib i ted  Med i c a t ion s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
 S a f e t y  Mon i to r in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
 S tud y  Sa f e t y  P r o c edu r e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 8  
 S tud y  P ro cedu r e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 In fo rm ed  Con s en t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 In c lu s ion  and  E x c lu s ion  C r i t e r ia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 D emog ra ph i c s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 M ed i ca l  H i s to r y  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 Ph y s i ca l  E xam ina t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
 H e igh t ,  W e igh t ,  an d  BM I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 9  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368813]  /  Ind ep end en t  E th i c s  Comm i t te e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 0  
 S tud y  Mon i to r in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 0  
 On s i t e  Aud i t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
 S tud y  D e v i c e  A c coun ta b i l i t y  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
 P a t i en t  In fo rm a t ion  and  In fo rm ed  Con s en t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
 P a t i en t  Con f id en t i a l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 2  
 In v e s t i g a to r  Comp l i an ce  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 2  
9 .0  STUDY  COMPLET ION  PROCEDURES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368814] s  Re ten t ion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
 Co mmun i c a t ion  o f  S tud y  Re su l t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3  
 E th i c s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
10 .0  REFERENCES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44  
11 .0  APPEND ICES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46  
 Pep t am en ® 1 .5  Nu t r i t ion  In fo rm a t ion  - Un f la vo r ed  (N e s t l e  H e a l th  S c i en ce )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 6  
 Imp a c t  Pep t id e  1 .5  Nu t r i t ion  In fo rm a t ion  - Un f la vo r ed  (N e s t l é  H e a l th c a r e  Nu t r i t ion )  . . . . . . . . . . . . . .  [ADDRESS_368815]  OF  TABLES  
Tab le  1 :  S chedu le  o f  E ven t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7 
Tab le  2:  C l in i ca l  Labo ra to r y  Tes t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  [ADDRESS_368816]  OF  F IGURES  
F igu re  1 :  Re l i zo rb  Dev i ce  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16  
F igu re  2 :  Enz yme  Hyd ro ly s i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17  
 
  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368817] -460  Rh i zopus  O r yzae  L ipase  ( s yn onymous  w i th  FCS /enz yme )  
ALCT -[ADDRESS_368818] iog ram  
eCRF  E lec t ron i c  Case  Repo r t  Fo rm  
EF IC  En te ra l  Feed ing  In -l ine  Ca r t r idge  
EPA  E i cosapen taeno i c  ac id  
EP I  E xoc r ine  Panc rea t i c  Insu f f i c ienc y  
FA  Fa t ty  A c id  
FCS /Enz yme  C omp lex  Food  Con tac t  Subs tance /enz yme  comp lex  
FDA  Food  and  D rug  Adm in i s t ra t ion  
fND  Fo r t i f ied  Nu t r i t iona l  D r ink  
GCMS  Gas  Ch roma tog raphy  Mas s  Spec t rome t ry  
G I  Gas t ro in tes t ina l  
GRAS  Gene ra l l y  Recogn i zed  A s  Sa fe  
G-tube  Gas t ros tom y  Feed ing  Tube  
HDL  H igh -Dens i t y  L ipop ro te in  
ICF  In fo rmed  Consen t  Fo rm  
ICH  In te rna t iona l  Con fe rence  on  Ha rmon i za t ion  
IEC  
IFU  Independen t  E th i c s  Comm i t tee  
Ins t ruc t ions  fo r  Use  
IRB  Ins t i tu t iona l  Rev iew  Boa rd  
kca l  K i loca lo r ie  
LA  L ino le i c  A c id  
LCPUFA  Long -Cha in  Po l yunsa tu ra ted  Fa t t y  A c id  
LCT  Long -Cha in  T r ig ly ce r ide  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  13  o f  47  LDL  Low -Dens i ty  L ipop ro te in  
MS /MS  Mas s  Spec t rome t r y /Mas s  Spec t rome t r y  
PERT  Panc rea t i c  Enz yme  Rep lacemen t  The rapy  
PfND  
 
P I  P re -hyd ro l y zed  Fo r t i f ied  Nu t r i t iona l  D r ink  (Pos t  exposu re  to  
ALCT -46 0) 
P r inc ipa l  Inves t iga to r  
RBC  Red  B lood  Ce l l s  
RD  Reg i s te red  D ie t i t ian  
RO  Rh izopus  o r yzae  
SAE  Se r ious  Adve r se  E ven t  
TG   
UADE  T r ig ly ce r ide s 
Unan t i c ipa ted  Adve r se  De v i ce  E f fec t s  
ULN  Uppe r  L im i t  o f  No rma l  
UPLC -MS /MS  U l t ra -h igh  Pe r fo rmance  L iqu id  Ch roma tog raphy –Tandem  
Spec t rome te r   
  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  14  o f  47  1 .0  STUDY  OVERV IEW  
Th i s  i s  a  mu l t i cen te r  open  labe l  s tudy  to  eva lua te  the  e f fec t  o f  sus ta ined  Re l i zo rb TM  use  
du r ing  en te ra l  tube  feed ing  on  fa t  abso rp t ion ,  as  we l l  as  sa fe ty  an d  to le rab i l i ty  o f  
sus ta ined  Re l i zo rb  use ,  in  pa t ien t s  w i th  cy s t i c  f ib ros i s  (CF )  w i th  exoc r ine  panc rea t i c  
insu f f i c ienc y  (EP I )  who  a re  rece i v ing  en te ra l  nu t r i t ion  as  pa r t  o f  the i r  nu t r i t ion  ca re  p lan . 
An  es t ima ted  35 -40  ma le  and  fema le  sub jec t s  w i l l  be  rec ru i ted  to  y ie ld  30  eva luab le  
sub jec t s  who  comp le te  the  s tudy  th rough  a t  leas t  V i s i t  4  a t  60  day s .   Sub jec t s  mus t  be  
≥[ADDRESS_368819]  sem i -e lemen ta l  fo rmu la  (Pep tamen ® 1 .5 )  and  use  o f  
panc rea t i c  enz yme  rep lacemen t  the rapy  (PERT )  w i th  en te ra l  tube  feed ing  w i l l  be  
reco rded .  Fo l low ing  the  run  in  pe r iod ,  sub jec t s  w i l l  use  Re l i zo rb  wh i le  rece i v ing  a  sem i -
e lemen ta l  fo rmu la  (Impac t ® Pep t ide  1 .5 )  w i th  a  re la t i ve l y  inc reased  ra t io  o f  long  cha in  
t r ig ly ce r ides  (LCT )  to  med ium  cha in  t r ig ly ce r ides  (MCT )  fo r  90  day s .  Use  o f  PERT  in  
con junc t ion  w i th  en te ra l  tube  feed ing  w i l l  be  d i s con t inued  du r ing  th i s  90  day  pe r iod .  
P lasma  concen t ra t ion  o f  re levan t  long -cha in  po l yunsa tu ra ted  fa t t y  ac id  (LCPUFA )  such  
as  docosahexaeno i c  ac id  (DHA ;  C :22 :6n -3 )  and  e i cosapen taeno i c  ac id  (EPA ;  C20 :5n -
3 )  w i l l  be  measu red  as  a b ioma r ke r  o f  fa t  abso rp t ion ,  a long  w i th   t i s sue  ac c re t ion  o f  
DHA  and  EPA  as ses sed  by  [CONTACT_301847] t  o f  e ry th rocy te  m emb rane  leve l s ,  
de te rm ina t ion  o f   changes  in  the  p lasma  fa t ty  ac id  p ro f i le ,  p lasma  fa t  so lub le  v i tam in  
and  se rum  p ro te in  concen t ra t ions ,  a t  s tudy  en t r y  (Day  -14 ) ,  a t  base l ine  (Day  0 ) ,  and  
du r ing  Re l i zo rb  use  a t  30  day  in te r va l s  (Day s  30 ,  60 ,  and  90 ) . 
2 .0   SC IE NT IF IC  AND  CL IN ICAL  BACKGROUND  
A  dec rease  in  panc rea t i c  l ipase  sec re t ion  as soc ia ted  w i th  impa i red  exoc r ine  panc rea t i c  
func t ion  resu l t s  in  ma ld iges t ion  and  ma labso rp t ion  o f  fa t s  and  reduced  to ta l  ca lo r ie  
in take .1 EP I  inc ludes  acu te  cond i t ions  o r  ch ron i c  d i seases , such  as  CF ,  panc rea t i t i s ,  
panc rea t i c  cance r  as  we l l  as  in  e lde r ly  pa t ien t s and  p re te rm  in fan t s .2,3,4,5 
 
Co mp rom i sed  exoc r ine  panc rea t i c  ou tpu t  leads  to  a  lac k  o f  panc rea t i c  enz ymes , 
inc lud ing  bu t  mos t  no tab l y l ipas e.  L ipase  func t ion  i s  cons ide red  c r i t i ca l  to  ma in ta in  
ca lo r i c  in take ,  s ince  9  k ca l  o f  ene rgy  i s  de r i ved  pe r  g ram  o f  fa t , ve r sus  4  k ca l  o f  ene rgy  
pe r  g ram  o f  p ro te in  o r  ca rbohyd ra te .  Fa t s  va r y ing  in  fa t ty  ac id  ca rbon  cha in  leng ths  a re  
hyd ro ly zed  (d iges ted )  and  me tabo l i zed  d i f fe ren t ly .  Sho r t  cha in  t r ig ly ce r ides  (C :2  – C:4 )  
and  MCT s  (C :6-C:12 )   a re  abso rbed  d i rec t ly  th rough  th e  v i l l i  o f  the  in tes t ina l  mucosa .  
MCT s  can  be  read i l y  abso rbed  due  to  the i r  sho r te r  cha in -leng th  and  the  res idua l  
ac t i v i ty  o f  gas t r i c  l ipase ,  even  in  panc rea t i c  comp rom i sed  pa t ien t s .  LCT s  hav e  fa t t y  
ac ids  o f  >12  ca rbons  (C :14 -C:24 ) .  LCT s  a re  no t  d i rec t ly  abso rbed  bu t  ins tead  mus t  f i r s t  
be  hyd ro ly zed  in to  fa t ty  ac ids  and  monog l y ce r ides  by  [CONTACT_301848] t i c  l ipase  be fo re  
abso r pt ion  can  take  p lace  in  the  sma l l  in tes t ine .  Once  fa t ty  ac ids  and  monog l y ce r ides  
a re  abso rbed ,  they  a re  t ranspo r ted  to  the  l i ve r  and ,  u l t ima te ly , to  t i s sues  in  the  body  fo r  
va r ious  phy s io log i ca l  pu rposes . 6 S ince  long  cha in  fa t ty  ac ids ,  in  pa r t i cu la r  LCPUFA s ,  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368820] s  such  as  omega -3  fa t t y  ac ids  DHA  and  
e i cosapen taeno i c  ac id  (EPA )  and  omega -6  fa t ty  ac id  a rach idon i c  ac id  (AA )  a re  
s t ruc tu ra l  componen t s  o f  memb ranes  and  a l so  b io log i ca l  med ia to r s  invo l ved  in  the  
regu la t ion  o f  va r ious  phy s io log i ca l  func t ions .  MCT s ,  when  subs t i tu ted  fo r  LCT s ,  have  
been  shown  to  inc rease  ene rgy  expend i tu re  and  sa t ie t y  lead ing  to  reduced  ove ra l l  
ca lo r i c  in take  and  reduced  body  fa t  mas s ,  mak ing  them  a  poo r  long -te rm  ene rgy  
sou r ce  fo r  nu t r i t iona l ly  comp rom i sed  pa t ien t s . [ADDRESS_368821]  a  c r i t i ca l  ro le  in  the  compos i t ion ,  deve lopmen t  
and  func t ion  o f  hea r t ,  l i ve r ,  and  neu ra l  ( re t ina  and  b r a in )  t i s sues  and  in f lamma to r y  and  
immuno log i ca l  sy s tem s .[ADDRESS_368822]  been  ide n t i f ied  in  the  
b lood  and  t i s sues  o f  peop le  w i th  CF  w i th  dec reased  leve l s  o f  DHA  as  we l l  the  es sen t ia l  
long -cha in  fa t ty  ac id  l ino le i c  ac id  (LA ) ,  and  inc reased  leve l s  o f  AA ,  as  we l l  as  e leva ted  
leve l s  o f  MCT s .11  Fa t ty  ac id  imba lances  in  the  omega -3  (DHA ,  EPA )  to  the  omega -6  
(AA )  ra t io  may  con t r ibu te  to  the  in f lamma to ry  cha rac te r i s t i c s  o f  CF  lung  d i sease  and  
gas t ro in tes t ina l  pa tho logy .[ADDRESS_368823]  s ign i f i can t  de f i c ienc ies  in  the  abso rp t ion  o f  bene f i c ia l  long -cha in  fa t ty  ac ids  
tha t  a re  impo r tan t  fo r  ach iev ing  adequa te  we igh t  ga in  and  c r i t i ca l  to  co r rec t ing  fa t ty  
ac id  imba lances , as  we l l  as  ma in ta in ing  good  ove ra l l  hea l th . 11 ,12 ,13  
 
To  imp rove  ca lo r i c  in take  and  a vo id  ma lnu t r i t ion , many  ind i v idua l s  w i th  EP I  u t i l i ze  
en te ra l  feed ing  as  a  supp lemen t  to  da i l y  d ie ta r y  in take .  Due  to  incomp le te  fa t  
hyd ro ly s i s ,  c u r ren t  en te ra l  feed ing  p rac t i ce  re l ies  on  la rge  vo lumes  (1 ,000  mL  o r  mo re )  
o f  h igh  ca lo r ie ,  nu t r ien t -dense  l iqu id  fo rmu la  de l i ve red  ove r  8-16  hou r s  o r  longe r .  The  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  16  o f  47  la rge  vo lume  requ i remen t s ,  coup l ed  w i th  poo r  fa t  hyd ro ly s i s  and  abso rp t ion ,  causes  
b loa t ing  in  the  mo rn ing  tha t  resu l t s  in  poo r  ca lo r i c  in take  a t  b reak fas t .  The  h igh  vo lume  
o f  en te ra l  fo rmu la  a l so  add s a  s ign i f i can t  ca rbohyd ra te  load  ( ~200  g  o f  ca rbohyd ra tes  
fo r  typ i ca l  1 ,000  mL  o f  en te r a l  fo rmu la )  tha t  may  con t r ibu te  to  the  deve lopmen t  o r  
exace rba t ion  o f  CF  re la ted  d iabe tes  (C FRD ).  
 
Fo r  pa t ien t s  w i th  EP I  who  rece i ve  en te ra l  nu t r i t ion , p ro te ins  can  be  p rov ided  p re -
hyd ro ly zed  in  eas i ly  abso rbed  pep t ide  fo rm  in  sem i -e lemen ta l  fo rmu las .  Un fo r tuna te ly ,  
fa t ty  ac ids  a re  inhe ren t ly  uns tab le ,  so  fa t  in  en te ra l  fo rmu las  a re  p rov ided  in  the  stab le  
t r ig ly ce r ide  fo rm .  A s  p rev ious l y  no ted ,  LCT s  mus t  be  hyd ro l y zed  by  l ipase  to  fo rm  
monog l y ce r ide s and  fa t ty  ac id s, be fo re  no rma l  abso rp t ion  and  u t i l i za t ion  in  the  body .  
 
A l c res ta  Pha rmaceu t i ca l s ,  Inc .  (A l c res ta )  has  de ve loped  Re l i zo rb  to  cons i s ten t l y  and  
e f f i c ien t ly  hyd ro ly ze  the  fa t s  in  en te ra l  tube  feed ing  in  o rde r  to  p ro v ide  the  bene f i t  o f  
read i l y  abso rbab le  fa t s  f rom  a  g i ven  en te ra l  fo rmu la ,  in  the i r  fa t ty  ac id  and  
monog l y ce r ide  fo rm ,  to  pa t ien t s  w i th  EP I  o r  l ip id  ma labso rp t ion .  Re l i zo rb  i s  a  
s ing le -use ,  ex -v i vo ,  po in t -o f -ca re  dev i ce  des igned  to  m im i c  the  func t ion  o f  panc rea t i c  
l ipase  by  p re -hyd ro ly z ing  fa t s  f rom  the i r  na tu ra l  t r ig ly ce r ide  fo rm ,  as  con ta ined  in  
en te ra l  fo rmu la ,  in to  the i r  abso rbab le  f ree  fa t ty  ac id  and  monog l y ce r ide  fo rm s ,  
m in im i z ing  the  bu rden  o f  en te ra l  feed ing  to  ca reg i ve r s  and  pa t ien t s .  
  
 Desc r ip t ion  o f  Re l i zo rb  
Re l i zo rb  i s  a  s ing le -use ,  po in t -o f -ca re  d iges t i ve  enz yme  ca r t r idge  tha t  connec t s  in -l ine  
w i th  ex i s t ing  en te ra l  pump  feed  se t s  and  pump  ex tens ion  se t s .  Re l i zo rb  i s  des igned  to  
hyd ro ly ze  f a t s  co n ta ined  in  the  en te ra l  fo rmu las .  By  [CONTACT_301844] z ing  fa t s  f rom  en te ra l  
fo rmu las ,  Re l i zo rb  a l low s  fo r  the  de l i ve r y  o f  abso rbab le  fa t t y  ac ids  and  monog l y ce r ides  
fo r  pa t ien t s  who  re ly  on  supp lemen ta l  en te ra l  ( tube )  feed ing . 
 
F igu re  1:   Re l i zo rb  Dev i ce  
 
 
R e l i zo rb  ( c en t e r )  conn e c t in g  w i th  a  pump  fe ed  tub e  ( l e f t )  and  th e  tub e  to  th e  p a t i en t  ( r i gh t ) .  PLEASE  READ  A ND  FULLY  UNDERSTAND  THESE  INSTRUCT ION S  
FOR  USE  BEFORE  US ING  REL IZORB . ™
1 .0   IND ICAT IONS  FOR  US E  
RE L IZORB  is  ind ica te d  fo r  u s e  in  a du l t s  to  hyd ro ly ze  fa t s  in  e n te ra l  fo rmu la .  
2 .0   DESCR IPT ION 
RE L IZORB  is  a  s ing le -u s e ,  po in t -o f - ca re  d ig e s t ive  e n z yme  ca r t r idg e  tha t  conne c t s  
in - l ine  w i th  e x is t ing  e n te ra l  pump  fe e d  s e t s  a nd  pump  e x te n s ion  s e t s .  RE L IZORB  is  
de s ig ne d  to  h yd ro ly ze  ( d ig e s t )  fa t s  con ta ine d  in  the  e n te ra l  fo rmu la s ,  m im ick ing  the  
fun c t ion  o f  the  d ig e s t ive  e n z yme  l ipa s e  tha t  is  no rma l ly  s e c re te d  by  [CONTACT_301849] n c re a s ,  the  
bod y ’ s  d ig e s t ive  o rg a n .  B y  h yd ro ly z ing  ( d ig e s t ing )  fa t s  f rom  e n te ra l  fo rmu la s ,  RE L IZORB  
a l lows  fo r  the  de l ive r y  o f  a b s o rba b le  fa t t y  a c id s  a nd  monog ly ce r ide s   
to  pa t ie n t s .  
 1  2 
 1  2 T u be  t o  P a t ie n t T u be  f r om  P um p 
I n le t Ou t le t R E L IZOR B 
F IGURE  1 :  RE L IZORB  (ce n te r )  conne c ts  w i th  pump  fe e d  tube  ( le f t )  a nd  tube  to  pa t ie n t  ( r ig h t ) . 
RE L IZORB  is  comp r is e d  o f  a  c le a r  cy l ind r ica l ,  p la s t ic  ca r t r idg e  w i th  a  s ing le  in le t  
conne c t ion  po r t  a nd  a  s ing le  pu rp le  ou t le t  conne c t ion  po r t .  T he  in le t  a nd  ou t le t  po r t s  
o f  RE L IZORB  a re  in te nde d  to  conne c t  in - l ine  w i th  e n te ra l  pump  fe e d  s e t s  a nd  pump  
e x te n s ion  s e t s .  In s ide  the  ca r t r idg e ,  the re  a re  sma l l  wh i te  be a d s .  T he  d ig e s t ive  e n z yme ,  
l ipa s e ,  is  cova le n t ly  bound  to  the  sma l l  wh i te  be a d s .  T he  l ipa s e -be a d  comp le x ,  
iL ipa s e TM  ( immob i l ize d  l ipa s e ) ,  is  re ta ine d  w i th in  the  ca r t r idg e  du r ing  u s e  b y  ﬁ l te r s  
on  bo th  e nd s  o f  the  ca r t r idg e .  T he  fa t  in  e n te ra l  fo rmu la s  is  h yd ro ly ze d  a s  i t  come s  in  
con ta c t  w i th  iL ipa s e  a s  the  fo rmu la  pa s s e s  th roug h  the  ca r t r idg e .  
 
           RE L IZOR B 
iL ipa s e 
( imm ob i l ized  l ipa s e ) I n le t 
F i l t e r F i l t e r Ou t le t 
F IGURE  2 :  RE L IZORB  a nd  i ts  ma jo r  compone n ts .  
3 .0   CONTRA IND ICAT ION S  
None . 
4 .0   WARN ING S  
• RE L IZORB  is  fo r  u s e  w i th  e n te ra l  fe e d ing  on ly .  The  “F e e d  On ly ”  le t te r ing  on  the  
RE L IZORB  pu rp le  ou t le t  is  the re  to  ide n t i f y  tha t  the  RE L IZORB  ca r t r idg e  is  in te nde d  
fo r  conne c t ion  to  e n te ra l  fe e d ing  l ine s  on ly .  
• RE L IZORB  s hou ld  no t  be  conne c te d  to  a ny  in t ra ve nou s  ( IV )  l ine ,  s e t  up ,  o r  s y s tem .  
• RE L IZORB  wa s  te s te d  a nd  demon s t ra te d  a  l ike l ihood  o f  m is conne c t ion  w i th  the  
fo l low ing  de v ice  a pp l ica t ion s : 
 oIn t ra va s cu la r  a nd  hypode rm ic  de v ice s 
 oB re a th ing  s y s tem s  a nd  d r iv ing  g a s  de v ice s 
 oU re th ra l /u r ina r y  de v ice s 
 o L imb  cu f f  in ﬂa t ion  de v ice s 
 oNe u ra x ia l  de v ice s 
• Me d ica t ion s  s hou ld  no t  be  a dm in is te re d  th roug h  the  RE L IZORB  ca r t r idg e .  Do  no t  
a dd  me d ica t ion s  to  the  e n te ra l  fe e d  l ine  in  be twe e n  the  pump  a nd  RE L IZORB  ( be fo re  
RE L IZORB ) .  T he  pa s s a g e  o f  me d ica t ion s  th roug h  RE L IZORB  may  a d ve r s e ly  a f fe c t  the  
me d ica t ion s  o r  the  a b i l i t y  o f  RE L IZORB  to  hyd ro ly ze  fa t s .  
• F ib ro s ing  C o lonopa th y  -  F ib ro s ing  co lonopa thy  is  a  ra re ,  s e r iou s  a dve r s e  re a c t ion  
a s s o c ia te d  w i th  h ig h -do s e  u s e  o f  pa n c re a t ic  e n z yme  re p la ceme n t  the r a p y  in  the  
t re a tme n t  o f  pa t ie n t s  w i th  c y s t ic  ﬁb ro s is .  T he  unde r ly ing  me c ha n ism  o f  ﬁb ro s ing  
co lonopa th y  rema in s  un known .  P a t ie n t s  w i th  ﬁb ro s ing  co lonopa th y  s hou ld  be  
c lo s e ly  mon i to re d  be ca u s e  s ome  pa t ie n t s  may  be  a t  r is k  o f  p rog re s s ing  to  s t r ic tu re  
fo rma t ion .  RE L IZORB  con ta in s  l ipa s e  e n z yme  tha t  is  no t  f rom  a  po rc ine  s ou rce .  T he  
l ipa s e  is  bound  to  the  be a d s ,  a nd  th is  l ipa s e -be a d  comp le x  ( iL ipa s e™ )  is  re ta ine d  
w i th in  the  RE L IZORB  ca r t r idg e .  C on t inue  to  fo l low  you r  ph y s ic ia n  g u ida n ce  a nd  
po r c ine  pa n c re a t ic  e n z yme  la be l ing  re g a rd ing  po rc ine  pa n c re a t ic  e n z yme  u s e   
whe n  u s e d  in  con jun c t ion  w i th  RE L IZORB .  5 .0   CAUT IONS  A ND  PRECAUT IONS 
• Do  no t  re -u s e  RE L IZORB .  RE L IZORB  is  a  s ing le -u s e  p rodu c t .  R e -u s e  ma y  re s u l t  i n  
con tam ina t ion  o f  the  p rodu c t .  I f  re -u s e d ,  RE L IZORB  may  no t  e f fe c t ive ly  h yd ro ly ze  fa t s . 
• Do  no t  b re a k ,  a l te r ,  o r  p la ce  e x ce s s  p re s s u re  on  a ny  pa r t  o f  the  RE L IZORB  ca r t r idg e .  
An y  comp rom is e  o f  the  s t ru c tu ra l  in te g r i t y  o f  RE L IZORB  ma y  le a d  to  imp rope r  
conne c t ion  to  e n te ra l  pump  fe e d  s e t s  a nd  pump  e x te n s ion  s e t s ,  e n te ra l  fo rmu la  
le a ka g e  o r  r is k  o f  con tam ina t ion .  
• Do  no t  u s e  RE L IZORB  a f te r  the  da te  ma r ke d  on  the  pou ch .  
• E n te r a l  fo rmu la s  con ta in ing  in s o lub le  ﬁbe r  s hou ld  NOT  be  u s e d .  In s o lub le  ﬁbe r  ma y  
c log  the  RE L IZORB  ca r t r idg e .  A  de ta i le d  l is t ing  o f  e n te ra l  fo rmu la s  compa t ib le  w i th  
RE L IZORB  ca n  be  found  a t  www .RE L IZORB . com / fo rmu la s . 
• RE L IZORB  is  de s ig ne d  fo r  u s e  w i th  e n te ra l  fe e d ing  pump  s y s tem s  w i th  lo w  ﬂo w /no  
ﬂo w  a la rm s .  RE L IZORB  is  NOT  in te nde d  fo r  u s e  w i th  g ra v i t y  fe e d  s y s tem s .  A  de ta i le d  
l is t ing  o f  pump s ,  fe e d  s e t s  a nd  pump  e x te n s ion  s e t s  compa t ib le  w i th  RE L IZORB  ca n  
be  found  a t  www .RE L IZORB . com /pump s . 
• In  o rde r  to  e n s u re  p rodu c t  pe r fo rma n ce ,  s to re  RE L IZORB  in  i t s  pou ch  e i the r  
re f r ig e ra te d  o r  a t  room  tempe r a tu re  ( 2 °C  to  27 °C ;  36 °F  to  80 °F ) .  
• T he  u s e  o f  RE L IZORB  a long  w i th  po rc ine  pa n c re a t ic  e n z yme  re p la ceme n t  the r a p y  
(PER T )  ha s  no t  be e n  inve s t ig a te d .  T he  a pp rop r ia te  do s e  a nd  a dm in is t ra t ion  o f  PER T  
s hou ld  be  e va lua te d  on  a n  ind iv idua l  ba s is .  P a t ie n t s  s hou ld  con t inue  to  fo l lo w  
ph y s ic ia n ’ s  g u ida n ce  a nd  PERT  p rodu c t  la be l ing  whe n  u s e d  in  con jun c t ion   
w i th  RE L IZORB . 
• T he  u s e  o f  RE L IZORB  ha s  no t  be e n  s tud ie d  in  pa t ie n t s  w i th  e xo c r ine  pa n c re a t ic  
in s u f ﬁc ie n c y  (E P I ) .  RE L IZORB  ha s  no t  be e n  e va lua te d  in  pe d ia t r ic  popu la t ion s . 
[ADDRESS_368824]  USE 
• RE L IZORB  is  in te nde d  fo r  s ing le -u s e  on ly .  A t  the  con c lu s ion  o f  the  fe e d ing ,  d is ca rd  
the  RE L IZORB .  Do  no t  s to re  o r  re -u s e  i t . 
• A  s ing le  RE L IZORB  ma y  be  u s e d  fo r  up  to  [ADDRESS_368825]  the  RE L IZORB  a f te r  u s e . 
• Up  to  2  RE L IZORB ’ s  ca n  be  u s e d  in  a  da y  ( 24 -hou r  pe r iod )  a nd  the re  a re  no  
re qu i reme n t s  on  the  amoun t  o f  t ime  be twe e n  u s ing  them .   
• RE L IZORB  ca n  be  u s e d  w i th  e n te r a l  pump  ﬂo w  ra te s  be twe e n  24  a nd  120  mL /h r .  
• RE L IZORB  is  in te nde d  fo r  u s e  a t  home  o r  me d ica l  in s t i tu t ion s  s u ch  a s  a  ho s p i ta l .  
P a t ie n t s  s hou ld  con s u l t  w i th  the i r  do c to r  o r  he a l th ca re  p rov ide r  be fo re  ma k ing  a n y  
cha ng e s  to  ﬂo w  ra te s  o r  vo lume  o f  e n te ra l  fo rmu la  u s e d .  
• RE L IZORB  ha s  be e n  e va lua te d  fo r  u s e  w i th  nume rou s  comme rc ia l ly  a va i la b le  e n te ra l  
fo rmu la s  a nd  be e n  s ho wn  to  e f ﬁc ie n t ly  h yd ro ly ze  ( d ig e s t )  fa t s  in to  a b s o rba b le  fa t t y  
a c id s  a nd  monog ly ce r ide s  in  mo s t  fo rmu la s .  
A  de ta i le d  l is t ing  o f  e n te ra l  fo rmu la s  te s te d  w i th  RE L IZORB ,  a long  w i th  a  s umma r y  o f  
the  h yd ro ly s is  a ch ie ve d ,  ca n  be  found  in  T a b le  1  lo ca te d  in  the  In  V i t ro  P e r fo rma n ce  
C ha ra c te r is t ic s  s e c t ion  a nd  a t  www .RE L IZORB . com / fo rmu la s . 
7 .0   REL IZORB ™ SET -UP  PROCEDURE  A ND  USE 
P a t ie n t s  s hou ld  re v iew  the  fo l low ing  RE L IZORB  in s ta l la t ion  in s t ru c t ion s  be fo re  u s e .  
1 .  S e t  up  the  pump  a nd  fe e d  s e t  pe r  the  pump  ma nu fa c tu re r ’s  in s t ru c t ion s .  P r ime  th e  
fe e d  s e t  pe r  the  ma nu fa c tu re r ’ s  in s t ru c t ion s . 
2 .  R emo ve  the  RE L IZORB  f rom  i t s  pou ch .  E xam ine  the  RE L IZORB .  
Do  no t  u s e  the  RE L IZORB  i f : 
 othe  pou ch  s e a l  is  b ro ke n 
 othe  RE L IZORB  is  dama g e d 
 othe  RE L IZORB  ha s  be e n  p re v iou s ly  u s e d 
3 .  
f rom  the  pump  tub ing  in to  the  in le t  o f  the  RE L IZORB  w i th  a  tw is t ing  a nd  pu s h in g  
mo t ion  un t i l  s e cu re . 
 1  2 R E L IZOR B 
T u be  f r om  P um p 
I n le t Ou t le t 
F IGURE  3 : 
4 .  F o l low  the  pump  ma nu fa c tu re r ’s  in s t ru c t ion s  to  p r ime  the  fe e d ing  fo rmu la  th roug h  
to  the  ou t le t  o f  the  RE L IZORB . 
5 .  
tha t  conne c t s  to  the  pa t ie n t . 
    T u be  t o  P a t ie n t 
I n le t Ou t le t 
 1  2 R E L IZOR B 
F IGURE  4 
6 .  F o l low  the  pump  ma nu fa c tu re r ’s  in s t ru c t ion s  to  p r ime  the  fe e d ing  fo rmu la  to  th e  
e nd  o f  the  pump  e x te n s ion  s e t . 
7 .  
w i th  fe e d ing . 
WARN ING : 
the y  mu s t  be  in t rodu ce d  AF TER  RE L IZORB  ( i .e .  be twe e n  RE L IZORB  a nd  the  pa t ie n t ) .  T he y  ma y  
pa t ie n t  a s  s hown  be low . 
R E L IZOR B P a t ie n t 
P um p Y- c o n n e c t o r 
E x t e n s io n  S e t D ow n s t r e am 
Me d i c a t io n s  o r  
O t h e r  S o l u t io n s 
Ma y  B e  A d d e d  H e r e 
F IGURE  5 :  Me d ica t ion s  ma y  be  a dde d  be twe e n  RE L IZORB  a nd  pa t ie n t . NOTE : 
NOTE :  
u s e  the  fo l low ing  s te ps : 
 o P a u s e  the  pump  fo l low ing  the  pump  ma nu fa c tu re r ’ s  in s t ru c t ion s 
 oD is conne c t  the  cu r re n t  RE L IZORB  f rom  the  pump  e x te n s ion  s e t 
 oR emo ve  the  cu r re n t  RE L IZORB  f rom  the  pump  fe e d  s e t 
 oC onne c t  the  new  RE L IZORB  to  the  pump  fe e d  s e t  fo l low ing  S te p  3 
 oP r ime  the  e n te ra l  fo rmu la  th roug h  to  the  e nd  o f  the  RE L IZORB  fo l low ing  S te p  4 
 oC onne c t  the  new  RE L IZORB  to  the  pump  e x te n s ion  s e t  fo l low ing  S te p  5 
 o F o l low  S te p  7  to  re - s ta r t  e n te ra l  fo rmu la  de l ive r y 
8 .0   D ISASSEMBLY  A ND  D ISPOSAL 
• Whe n  fe e d ing  is  comp le te ,  d is conne c t  the  RE L IZORB  f rom  the  pump  e x te n s ion  s e t  
a nd  pump  tub ing  s e t .  
• P la ce  the  RE L IZORB  ba ck  in to  i t s  o r ig ina l  pou ch ,  s e a l  the  pou ch  a nd  d is ca rd . 
[ADDRESS_368826] IO N  
RE L IZORB  is  de s ig ne d  to  h yd ro ly ze  ( d ig e s t )  fa t s  con ta ine d  in  e n te ra l  fo rmu la s .  RE L IZOR B  
con ta in s  the  d ig e s t ive  e n z yme  l ipa s e  bound  to  be a d s  ( iL ipa s e ™) .  B y  h yd ro ly z ing  fa t s  
f rom  e n te ra l  fo rmu la s ,  RE L IZORB  a l lows  fo r  the  de l ive r y  o f  a b s o rba b le  fa t t y  a c id s  a n d  
monog ly ce r ide s .  L ike  huma n  pa n c re a t ic  l ipa s e ,  the  l ipa s e  in  RE L IZORB  ha s  s n -1 ,  s n - 3  
s e le c t iv i t y  in  the  h yd ro ly s is  o f  t r ig ly ce r ide  fa t s  (F ig u re  6 ) .  Whe n  e n te ra l  fo rmu la  ﬂow s  
th roug h  RE L IZORB ,  the  l ipa s e  bound  to  the  be a d s  h yd ro ly ze s  fa t s  in  the i r  t r ig ly ce r id e  
fo rm ,  in c lud ing  impo r ta n t  long - cha in  po lyun s a tu ra te d  fa t s  ( LCPUF A s ) ,  re le a s ing  ome g a - 3  
( do co s a he xa e no ic  a c id  (DHA )  a nd  e ico s a pe n ta e no ic  a c id  (E P A ) )  a nd  ome g a -6  ( l ino le i c  
a c id  ( LA )  a nd  a ra ch idon ic  a c id  (AA ) )  in to  the i r  a b s o rba b le  fa t t y  a c id  a nd  monog ly ce r id e  
fo rm s .  T he  iL ipa s e ™ is  re ta ine d  w i th in  the  RE L IZORB  ca r t r idg e  b y  two  ﬁl te r s  a s  e n te ra l  
fo rmu la  ﬂows  th roug h  RE L IZORB .  
G L YC E R O L 
B A CK BONE 
MONOG L YC E R IDE 
F A T TY  AC IDS 
TR IG L YC E R IDE SN -1 
SN -2 
SN -3 
AB SOR B AB L E  FORM L ip a s e 
F IGURE  6 :  Hyd ro ly s is  o f  fa t  by  l ipa s e  in to  monog ly ce r ide  a nd  f re e  fa t ty  a c ids . 
[ADDRESS_368827] IC S  
A  s e r ie s  o f  in  v i t ro  e xpe r ime n t s  u s ing  a n  e n z yme -ba s e d  fa t t y  a c id  qua n t iﬁca t ion   
a s s a y  wa s  condu c te d  to  me a s u re  fa t t y  a c id  re le a s e  re s u l t ing  f rom  the  u s e  o f  the  
RE L IZORB  ca r t r idg e .  
RE L IZORB  is  de s ig ne d  to  be  compa t ib le  w i th  bo th  po lyme r ic  a nd  s em i -e leme n ta l  
fo rmu la s .  RE L IZORB  wa s  te s te d  a nd  is  compa t ib le  a c ro s s  a  ra ng e  o f  e n te ra l  fe e d ing  
pump  ﬂo w  ra te s  ( 24 -120  mL /hou r )  a nd  comme rc ia l ly  a va i la b le  e n te ra l  fo rmu la s  w i th  
va r y ing  p rodu c t  cha ra c te r is t ic s  a nd  compone n t s  ( ca lo r ie s ,  fa t ,  ome g a -3 ;  T a b le  1 ) .  
RE L IZORB  is  no t  compa t ib le  w i th  e n te r a l  fo rmu la s  con ta in ing  in s o lub le  ﬁbe r .  
R ep re s en ta t ive  F a t  Hyd ro ly s is  Da ta  Us ing  RE L IZORB 
RE L IZORB  ha s  be e n  s hown  to  h yd ro ly ze  >90%  o f  fa t  in  mo s t  e n te ra l  fo rmu la s  
whe n  te s te d  w i th  500  mL  o f  e n te ra l  fo rmu la  a t  a  ﬂow  ra te  o f  120  mL /hou r  (T a b le  1 ) .  
C ompa ra b le  o r  imp ro ve d  fa t  h yd ro ly s is  ha s  a ls o  be e n  s hown  whe n  RE L IZORB  wa s  u s e d  
w i th  e n te r a l  fe e d ing  pump  ﬂo w  ra te s  be twe e n  24 -120  mL /hou r . 
TABLE  1 :  F a t  hyd ro lys is  fo r  rep res en ta t ive  en te ra l  fo rmu las  (500  mL )  us ing  RE L IZORB  a t   
120  mL /hou r 
PR ODUCT FA T  (g ) MCT  /  L CT  
RAT IO* *  
(% ) CA LO R IE S  
(kc a l )OMEGA - 3   
DHA  &  EP A  
(g ) %  FA T  
HYDROLYS I S   
W IT H  
RE L IZ ORB *§ 
NUTREN ® 2 . 0  52 74 :25  1 ,000 ->90% 
TW OCAL ® HN 43 19 :81 950 -51% 
IMP AC T®  
PEPT IDE  1 .5 32 50 :50 750 2 .45  >90% 
PEPTAMEN ® 1 .5 ^ 28 70 :30 750 ->90% 
PEPTAMEN  AF ® ^ 27 50 :50 600 1 .2 >90% 
V ITAL  A F   
1 .2  C AL™^ 26 45 :55 570 1 .9 84% 
PEPTAMEN ®^20 70 :30 500 -85% 
NUTREN ® 1 .0 19 25 :75 500 ->90% 
*  %  fa t  hyd ro ly s is  is  e s t ima te d  ba s e d  on  la be l  c la im   
§  B a s e d  upon  te s t ing  f rom  da te  o f  ma nu fa c tu re   
 
 
* *  MCT  =  me d ium  cha in  t r ig ly ce r ide s ;  LCT  =  long  cha in  t r ig ly ce r ide s   
 
F a t  h yd ro ly s is  ra te s  ma y  d i f fe r  fo r  e n te ra l  fo rmu la s  tha t  ha ve  no t  be e n  te s te d . 
F o r  a  mo re  de ta i le d  l is t ing  o f  compa t ib le  e n te ra l  fo rmu la s  te s te d  w i th  RE L IZORB ,  a long  
w i th  a  s umma r y  o f  the  hyd ro ly s is  a ch ie ve d ,  v is i t  www .RE L IZORB . com / fo rmu la s .  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  17  o f  47  Re l i zo rb  i s  comp r i sed  o f  a  c lea r  c y l ind r i ca l ,  p las t i c  ca r t r idge  w i th  a  s ing le  in le t  
connec t ion  po r t  and  a  s ing le  pu rp le  ou t le t  connec t ion  po r t  (F igu re  1 ) .  The  in le t  and  
ou t le t  po r t s  o f  Re l i zo rb  a re  in tended  to  connec t  in -l ine  w i th  en te ra l  pump  feed  se t s  and  
pump  ex tens ion  se t s .  Ins ide  the  ca r t r idge , the re  a re  sma l l  wh i te  beads . The  d iges t i ve  
enz yme ,  l ipase ,  i s  cova len t l y  bound  to  po lyme r i c  beads .  The  l ipase -bead  comp lex ,  
iL ipase TM  ( immob i l i zed  l ipase ) ,  i s  re ta ined  w i th in  the  ca r t r idge  du r ing  use  by  f i l te r s  on  
bo th  ends  o f  the  ca r t r idge .  The  fa t  in  en te ra l  fo rmu las  i s  hyd ro ly zed  as  i t  comes  in  
con tac t  w i th  iL ipase  as  the  fo rmu la  pas ses  th rou gh  the  ca r t r idge . The  iL ipase  i s  
re ta ined  w i th in  the  ca r t r idge  and  i t  i s  impo r tan t  to  no te  tha t  on ly  m inu te  quan t i t ies  o f  the  
l ipase  have  the  po ten t ia l  to  ex i t  Re l i zo rb .  Re l izo rb  was  c lea red  by  [CONTACT_301845]  
D rug  Adm in i s t ra t ion  (FDA )  Cen te r  fo r  Dev i ces  a nd  Rad io log i ca l  Hea l th  (CDRH )  as  a  
C las s  2  low -r i s k  dev i ce  and  i s  ind i ca ted  fo r  use  in  adu l t s  to  hyd ro ly ze  fa t s  in  en te ra l  
fo rmu la .   
 Ac t ive  Componen t  and  Mechan ism  o f  Ac t ion  
The  ac t i ve  componen t  o f  Re l i zo rb  i s  a  l ipase  enz yme  tha t  i s  immob i l i zed  on  po lyme r i c  
beads ,  co l lec t i ve ly  ca l led  iL ipase . 
 
A vo lume  o f  500  mL  o f  en te ra l  fo rmu la  used  fo r  ove rn igh t  feed ing  w i l l  typ ica l ly  
p rov ide  600  k i loca lo r ies  and  27  g  o f  fa t .  Re l izo rb  is  des igned  to  cons is ten t ly  and  
e f f ic ien t ly  hyd ro ly ze  app rox ima te ly  90%  o f  ava i lab le  fa ts  in to  abso rbab le  fa t ty  ac ids  
and  monog ly ce r ides .   
 
A  sens i t i ve  enz yme -based  f ree  fa t t y  ac id  quan t i f i ca t ion  as say  fo r  de tec t ing  med ium  
and  long -cha in  f ree  fa t t y  ac ids  was  used  to  measu re  fa t t y  ac id  re lease  resu l t ing  f rom  
the  ac t ion  o f  Re l i zo rb  ov e r  a  range  o f  cond i t ions .  Based  on  th i s  me thod ,  in  v i t ro  
ana l y s i s  demons t ra tes  tha t  fo r  mos t  en te ra l  fo rmu la  tes ted , app rox ima te l y  >90%  o f  fa t  
w i l l  be  hyd ro ly zed  a f te r  pas s ing  th rough  Re l i zo rb . 
 
F igu re  2:  En zyme  Hyd ro lys is  
 
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  18  o f  47   C l in ica l  Labe l ing  
One  Re l i zo rb  i s  pac kaged  in  a  s ing le  fo i l  pouch  w i th  an  inves t iga t iona l  use  labe l  
cus tom i zed  to  th i s  s tudy .  Each  sub jec t  and /o r  pa ren t / ca reg i ve r  w i l l  rece i ve  Ins t ruc t ions  
Fo r  Use  ( IFU )  tha t  p rov ides  de ta i led  ins t ruc t ions  on  the  ope ra t iona l  se tup  and  use  o f  
Re l i zo rb . 
   
 S to rage  Cond i t ions  
S to rage  cond i t ions  requ i re  tempe ra tu res  o f  2 °C  to  27  °C  (36  °F  to  80  °F )  ac co rd ing  to  
p roduc t  labe l ing .  Re l i zo rb  i s  no t  to  be  f rozen  ( -20  °C  o r  -4 °F ) .  Spec i f i ca t ions  rega rd ing  
s to rage  cond i t ions  a re  inc luded  in  the  IFU .   
 
 Study  Ra t iona le  and  Pu rpose  
En te ra l  nu t r i t ion  supp lemen t s ,  usua l ly  de l i ve red  as  a  noc tu rna l  tube  feed ing ,  a re  
p ro v ided  fo r  nu t r i t iona l ly  cha l lenged  pa t ien t s  w i th  EP I  to  suppo r t  nu t r i t iona l  s ta tus  and  
ma in ta in  o r  ga in  we igh t .  The re  a re  we l l -ac cep ted  bene f i t s  as so c ia ted  w i th  en te ra l  
nu t r i t ion , espec ia l ly  in  CF ,  bu t  use  va r ies  d rama t i ca l ly  among  cen te r s ,  rang ing  f rom  0% 
to  33%  o f  pa t ien t s  u t i l i z ing  en te ra l  nu t r i t ion  to  supp lemen t  da i ly  ca lo r i c  in take .  Cu r ren t  
en te ra l  nu t r i t ion  p rac t i ce  re l ies  on  la rge  vo lumes  o f  a nu t r ien t  dense  l iqu id  fo rmu la  
de l i ve red  o ve r  8 to  >12  hou r s .  Common  cha l lenges  in  the  cu r ren t  p rac t i ce  inc lude  
du ra t ion  o f  feed ing ,  c logg ing  o f  l ines  resu l t ing  in  pump  a la rm s ,  s leep  in te r rup t ion ,  the  
inab i l i ty  to  adm in i s te r  PERT  du r ing  con t inuous  o ve rn igh t  de l i ve r y  o f  the  en te ra l  
fo rmu la . PERT  i s  some t imes  adm in i s te red  be fo re ,  du r ing ,  and /o r  a f te r  en te ra l  tube  
feed ing  ses s ions . Howeve r ,  i t  i s  imp rac t i ca l  to  adm in i s te r  PERT  p roduc t s  ove rn igh t  tha t  
wou ld  p rov ide  fo r  adequa te  hyd ro ly s i s  o f  fa t .  Mo reove r ,  the  e f f i cacy  and  sa fe ty  o f  
PERT  p roduc t  use  in  con junc t ion  w i th  en te ra l  nu t r i t ion  has  no t  been  es tab l i shed .  PERT  
p roduc t  manu fac tu re r  p res c r ib ing  in fo rma t ion  wa rns  aga ins t  c rush ing  the  p roduc t  o r  
add ing  i t  to  fo rmu la ,  and  the  FDA  ad v i ses  tha t  panc rea t i c  enz yme  p roduc t s  a re  no t  
app ro ved  fo r  adm in i s t ra t ion  v ia  gas t ros tom y  tubes .  Symp tom s  o f  fa t  ma labso rp t ion  
such  as  nausea ,  b loa t ing  and  s tea to r rhea  due  to  incomp le te  hyd ro ly s i s  o f  fa t s  a re  o f ten  
repo r ted  to  be  inc reased  in  pa t ien t s  w i th  CF  who  rece i ve  en te ra l  nu t r i t ion .  
 
Some  mac ronu t r ien t s  in  en te ra l  fo rmu las ,  such  as  p ro te in ,  can  be  p repa red  p re -
hyd ro ly zed  in  a  pep t ide  fo rm  tha t  i s  s tab le  and  ava i lab le  to  be  read i ly  abso rbed .  In  
add i t ion ,  hyd ro ly s i s  o f  p ro te in  oc cu r s  in  the  s tomach  independen t  o f  panc rea t i c  
enz ymes .  The re fo re ,  pa t ien t s  w i th  EP I  theo re t i ca l ly  shou ld  no t  need  p ro tease  to  
ach ieve  adequa te  abso rp t ion  o f  pep t ides  and  am ino  ac ids  in  en te ra l  fo rmu las ,  a l though  
th i s  has  no t  been  inves t iga ted .  Due  to  poo r  s tab i l i ty  o f  fa t ty  ac ids , no  en te ra l  fo rmu la  
con ta in ing  hyd ro ly zed  fa t  has  been  manu fac tu red  to  da te .  Howeve r ,  hyd ro ly z ing  fa t s  a t  
the  t ime  o f  consump t ion  (po in t -o f -ca re )  a vo ids  th i s  p rob lem .  Thus , the  in tended  bene f i t  
o f  th i s  po in t -o f -ca re  app roach  w i th  Re l i zo rb  i s  tha t  fa t s  in  en te ra l  fo rmu la , inc lu d ing  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368828] s , a re  p re -hyd ro l y zed  ex -v i vo  jus t  be fo re  inges t ion  and  p ro v ided  in  a  fo rm  read i l y  
ava i lab le  fo r  abso rp t ion  in  ind i v idua l s  who  lac k  panc rea t i c  l ipase  o r  the  phy s io log i ca l  
capac i t y  to  d iges t  fa t .  
 
The  ob jec t i ves  o f  th i s  s tudy  a re  as  fo l low s :  
 
1 .  Demons t ra te  tha t  sus ta ined  use  o f  Re l i zo rb  in  con junc t ion  w i th  en te ra l  tube  
feed ing  w i thou t  concom i tan t  use  o f  PERT  resu l ts  in  an  inc rease  in  fa t  abso rp t ion  
as  ev idenced  by  [CONTACT_301850]  p lasma  concen t ra t ions  o f  LCPUFA s  such  as  DHA  
and  EPA ,  t i s sue  ac c re t ion  (R BC )  o f  omega -3  fa t ty  ac ids  such  as  DHA  and  EPA ,  
and  inc reased  concen t ra t ions  o f  fa t  so lub le  v i tam ins ;  
2 .  Show  tha t  se rum  p ro te in  leve l s  a re  ma in ta ined  desp i te  w i thd rawa l  o f  PERT  use  
as soc ia ted  w i th  en te ra l  tube  feed ing  w i th  sus ta ined  use  o f  Re l i zo rb  in  
con jun c t ion  w i th  en te ra l  tube  feed ing  us ing  a  sem i -e lemen ta l  fo rmu la ; 
3 .  Demons t ra te  the  sa fe t y  and  to le rab i l i ty  o f  sus ta ined  use  o f  Re l i zo rb  in  
con junc t ion  w i th  en te ra l  tube  feed ing ;  
4 .  E xp lo re  the  po ten t ia l  immunomodu la to r y  e f fec t  o f  inc reased  p lasma  
concen t ra t ions  o f  DHA  and  EPA  as  e v idenced  by  [CONTACT_301851] -6  to  
omega -3  fa t t y  ac id  ra t io  and  u r ina r y  leuko t r iene  concen t ra t ions . 
 
 Po ten t ia l  Bene f i ts  and  R isks  
Th i s  open -labe l  s tudy  i s  the  compan ion  s tudy  to  P ro toco l  0000497 ,  an  ongo ing  s tudy  
en ro l l ing  pa t ien t s  f rom  the  same  popu la t ion .   In  bo th  s tud ies  it  i s  expec ted  tha t ,  w i th  
Re l i zo rb  use ,  pa t ien t s  w i l l  expe r ience  a  dec rease  in  s ymp tom s  as soc ia ted  w i th  fa t  
ma l abso rp t io n ,  imp roved  fa t  abso rp t ion  and  ca lo r ie  in take ,  and  up ta ke  o f  
phy s io log i ca l ly  re levan t  fa t t y  ac ids  l i ke  DHA  and  EPA .  S ince  fa t  hyd ro ly s i s  oc cu r s  
ex -v i vo  in -l ine  w i th  the  en te ra l  feed ing  c i r cu i t ,  pa t ien t s  w i l l  no t  be  exposed  to  the  
enz yme  bu t  on l y  to  fo rmu la ,  w i th  fa t  in  a  read i ly  abso rbab le  fo rm  (fa t t y  ac id s an d  
monog l y ce r ide s ) . 
 
The  po r c ine  mode l  o f  EP I  i s  a  we l l -es tab l i shed  su rg i ca l  mode l  whe re  l iga t ion  o f  
panc rea t i c  duc t s  causes  a  to ta l  lac k  o f  panc rea t i c  enz ymes , inc lud ing  l ipase ,  
d im in i shed  leve l s  o f  b i ca rbona te , and  reduced  pH  in  the  duodenum .  L i ke  EP I  in  
humans , res idua l  gas t r i c  l ipase  rema ins .  EP I  p igs  have  s tea to r rhea ,  a r res ted  g row th ,  
fa t ty  ac id  de f i c ienc ies ,  as  we l l  as  common  gas t ro in tes t ina l  symp tom s  seen  in  peop le  
w i th  panc rea t i c  insu f f i c iency . 17  In  fou r  p re -c l in i ca l  s tud ies  us ing  th i s  mode l ,  use  o f  
Re l i zo rb  and  i t s  p ro to types  was  as soc ia ted  w i th  imp roved  g row th  as  we l l  as  labo ra to r y  
nu t r i t iona l  pa rame te r s .  Imp roved  to ta l  and  LCPUFA  fa t  abso rp t ion  was  demons t r a ted ,  
espec ia l ly  inc reases  in  p lasma  and  t i s sue  leve l s  o f  omega -3  and  omega -6  fa t s ,  
no rma l i za t ion  o f  b lood  fa t  p ro f i le  and  inc reases  in  o the r  nu t r i t iona l  pa rame te r s  (e .g . ,  fa t  
so lub le  v i tam ins ,  p ro te ins ) .  The re  was  a l so  a  dec rease  in  s igns  o f  ma labso rp t ion  in  
an ima l s  t rea ted  w i th  Re l i zo rb ,  and  the re  we re  no  obse r ved  ad ve r se  e ven t s  as soc ia ted  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368829] ® O r ig ina l  fo r t i f ied  w i th  10 mL  o f  a lgae  o i l , e i the r  as  a  p re -hyd ro ly zed  d r ink  
(P fND )  a f te r  exposu re  to  iL ipase  con ta ined  w i th in  a  mesh  bag  o r  as  a  non -hyd ro ly zed  
nu t r i t iona l  d r ink  ( fND ) .  No  se r ious  adve r se  e ven t s  oc cu r red  when  a  s ing le  PfND  and  
fND  we re  consumed .  Ad ve r se  e ven t s  we re  s im i la r  among  the  two  g roups ;  o ne  m i ld  
headache  (≤24h )  in  the  fND  g roup , and  th ree  un re la ted  s tudy  even t s  (den ta l  in fec t ion -
1 ,  headache -1 ,  vom i t ing -1 )  in  the  P fND  g roup .  Comp l iance  w i th  the  p ro toco l  was  100%  
w i th  bo th  nu t r i t iona l  d r ink s  consumed  w i th in  two  m inu tes .  No  subsequen t  G I  i s sues  
we re  repo r ted  a t  the  24h  sa fe t y  fo l low -up  ca l l  in  e i the r  g roup .  
 
In  a  second  s tu dy ,  pa t ien t s  w i th  p resumed  EP I  o ra l ly  consumed  a  s ing le  bo t t le  o f  
BOOST ® O r ig ina l  fo r t i f ied  w i th  10 mL  o f  a lgae  o i l ,  e i the r  as  a  p re -hyd ro ly zed  d r ink  
(P fND )  a f te r  exposu re  to  iL ipase  con ta ined  w i th in  a  mesh  bag  o r  as  a  non -hyd ro ly zed  
nu t r i t iona l  d r ink  ( fND ) .  The re  was  100%  comp l iance ,  w i th  a l l  sub jec t s  consum ing  the  
fu l l  vo lume  o f  P fND  and  fND .  The  hyd ro ly zed  d r ink  and  non -hyd ro l y zed  d r ink  we re  bo th  
we l l  to le ra ted  by  a l l  sub jec t s .  The re  was  no  d i f fe rence  in  pa la tab i l i ty  be tween  
hyd ro ly zed  and  non -hyd ro l y zed  d r ink .    Th ree  sub jec t s  expe r ienced  a  s tudy  even t  
fo l low ing  consump t ion  o f  fND  and  3  sub jec t s  expe r ienced  a  s tudy  even t  a f te r  
consump t ion  o f  P fND .  Headache  oc cu r red  in  one  sub jec t  in  each  t rea tmen t  g roup .   
One  ins tance  each  o f  fa t igue ,  d i z z ines s  and  nausea  we re  repo r ted .   Two  s tudy  even t s  
we re  cons ide red  t rea tmen t -re la ted :  abdom ina l  pa in  ( fND )  and  th roa t  i r r i ta t ion  (P fND ) .  
The re  we re  no  SAE s  in  the  s tudy .  
 
To  da te ,  the  obse r ved  r i s k s  o f  Re l i zo rb  use  a re  de te rm ined  to  be  low  based  on  
p rec l in i ca l  v a l ida t ion ,  inc lud ing  sa fe ty  eva lua t ion  in  an im a l  mode l s  as  we l l  as  c l in i ca l  
s tud ies  in  hea l thy  vo lun tee r s  and  peop le  w i th  EP I . Re l i zo rb  i s  c lea red  by  [CONTACT_301852]  a  
C las s  I I  ( low  r i s k )  dev i ce  fo r  use  in  adu l t s  to  hyd ro ly ze  fa t s  in  en te ra l  fo rmu la .  
Nonc l in i ca l  da ta  i s  ava i lab le  in  the  Inves t iga to r ’s  B rochu re  in  Sec t ion  11 . 0 tha t  suppo r t s  
con t inua t ion  o f  fu r the r  s tud ies .  
 
In  summa r y ,  the  po ten t ia l  bene f i t s  o f  pa r t i c ipa t ion  in  th i s  open  labe l  s tudy  inc lude  the  
pos s ib i l i ty  o f  imp roved  fa t  abso rp t ion  and  dec rease  in  gas t ro in tes t ina l  s ymp tom s  
re la ted  to  fa t  ma labso rp t ion .  Based  on  ava i lab le  p rec l in i ca l  and  c l in i ca l  da ta ,  the  r i s k  
p ro f i le  as soc ia ted  w i th  pa r t i c ipa t ion  in  th i s  open  labe l  s tudy  i s  low .  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368830]  EP I  and  a re  rece i v ing  en te ra l  
tube  feed ing .   In  th i s  s tudy ,  sub jec t s  w i l l  be  rece i v ing  an  en te ra l  fo rmu la  tha t  has  a  h i gh  
con ten t  o f  long  cha in  t r ig ly ce r ides  ( Impac t ® Pep t ide  1 .5 )  and  w i l l  be  us ing  Re l i zo rb  
du r ing  the i r  en te ra l  feed ing  in  p lace  o f  o the r  the rap ies  cu r ren t l y  used  to  a id  in  fa t  
abso rp t ion ,  such  as  panc rea t i c  enz yme  rep lacemen t  the rapy  (PERT ) .   P lasma  
concen t r a t ion  o f  re le van t  LCPUFA s  such  as  DHA  and  EPA  w i l l  be  measu red  as  a  
b ioma r ke r  o f  fa t  abso rp t ion .  T i s sue  ac c re t ion  o f  fa t ty  ac ids  DHA  and  EPA  as ses sed  by  
[CONTACT_301847] t  o f  e r y th rocy te  memb rane  leve l s  and  the  p lasma  fa t t y  ac id  p ro f i le  w i l l  be  
eva lua ted  as  add i t iona l  b ioma r ke r s  o f  fa t  abso rp t ion .  P lasma  fa t -so lub le  v i tam in  and  
se rum  p ro te in  concen t ra t ions  w i l l  a l so  be  measu red .  A l l  fa t ty  ac id ,  fa t -so lub le  v i tam in ,  
and  p ro te in  concen t ra t ions  w i l l  be  as ses sed  in  re la t ion  to  va lues  ob ta ined  a t  s tudy  
en t r y  (Day  -14 ) ,  a t  base l ine  (Day  0 ) ,  and  du r ing  Re l i zo rb  use  (Day s  30 ,  60 ,  and  90 ) .  
Sa fe t y  and  to le rab i l i ty  o f  sus ta ined  use  o f  Re l izo rb  w i l l  a l so  be  as ses sed  du r ing  use  
and  compa red  w i th  gas t ro in tes t ina l  s ymp tom s  reco rded  du r ing  the  obse r va t ion  phase  
o f  the  s tudy  (Day  -14  th rough  Day  -8) .   
E f f icacy   
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  du r ing  en te ra l  feed ings  on  fa t  abso rp t ion  
th rough  se r ia l  measu remen t s  o f  p lasma  and  t i s sue  (e ry th rocy te  memb rane )  
concen t ra t ions  o f  phy s io log i ca l ly  re levan t  LCPUFA s  such  as  DHA  and  EPA ,  as  we l l  
as  the  p lasma  fa t ty  ac id  p ro f i le  changes , as  b ioma r ke r s  o f  fa t  abso rp t ion .  
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  du r ing  en te ra l  feed ings  on  p lasma  
fa t -so lub le  v i tam in  concen t ra t ions .   
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  on  the  ra t io  o f  omega -6  to  omega -3  fa t t y  
ac ids  as  a  po ten t ia l  ind i ca to r  o f  immunomodu la t ion   
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  on  u r ina r y  leuko t r iene  leve l s  
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  on  se rum  p ro te in  leve l s  
• E va lua te  e f fec t  o f  sus ta ined  Re l i zo rb  use  on  g row th . 
 
Sa fe ty  
• E va lua te  the  sa fe t y  and  to le rab i l i ty  o f  sus ta ined  use  o f  Re l i zo rb  as  pa r t  o f  a  en te ra l  
feed ing  reg imen .   
 
 Endpo in ts  
E f f icacy  
• Change  o ve r  t ime  in  p lasma  concen t ra t ions  o f  LCPUFA s  such  as  DHA  and  EPA  
• Change  ove r  t ime  in  t i s sue  (e ry t h roc y te  memb rane )  fa t ty  ac id  concen t ra t ions  such  
as  DHA  and  EPA   
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  22  o f  47  • Change  o ve r  t ime  in  p lasma  fa t ty  ac id  p ro f i le  o f  LCPUFA s  
• Changes  o ve r  t ime  in  the  ra t io  o f  omega -6  to  omega -3  fa t t y  ac ids  in  p lasma  and  in  
t i s sue  (e r y t h roc y te  memb rane )  leve l s  
• Change  o ve r  t im e  in  p lasma  concen t ra t ions  o f  fa t  so lub le  v i tam ins  
• Change  o ve r  t ime  in  body  we igh t ,  BM I ,  and  we igh t  and  BM I  s tanda rd  s co res  
• Change  o ve r  t ime  in  se rum  p ro te in  concen t ra t ions  ( to ta l  p ro te in ,  p rea lbum in ,  
a lbum in ,  t rans fe r r in )  
• Change  o ve r  t ime  in  ma r ke r s  o f  in f lamma t ion  (u r ina r y  leuko t r ienes )  
 
Sa fe ty  
• F requenc y  and  se ve r i t y  o f  adve r se  e ven t s  and  unan t i c ipa ted  ad ve r se  de v i ce  e f fec t s  
(UADE s )  
• E va lua t ion  o f  c l in i ca l  and  labo ra to r y  f ind ings   
• Concom i tan t  med i ca t ion  as ses smen t  
• F requenc y  and  seve r i t y  o f  gas t ro in tes t ina l  s igns  and  s ymp tom s  (abdom ina l  pa in ,  
vom i t ing ,  los s  o f  appe t i te ,  b loa t ing ,  f la tu lence  and  s tea to r rhea )  
 
4 .0  STUDY  DES IGN  AND  PROCEDURES  
 En ro l lmen t  Goa ls  
Ma le  and  fema le  pa t ien t s  w i th  CF  and  EP I  w i l l  be  s c reened  fo r  the  s tudy  f rom  
app rox ima te l y  10  inves t iga t i ve  cen te r s  in  the  Un i ted  S ta tes .  App rox ima te ly  35  sub jec t s  
w i l l  be  en ro l led  in  the  s tudy  w i th  the  goa l  o f  ha v ing  a t  leas t  30  eva luab le  sub jec t s  
comp le t ing  the  s tudy  th rough  a t  leas t  V i s i t  4  (Day  60 ) .    
 
 Rep resen ta t i ve  Age  G roups  
 
Thi s  s tudy  w i l l  en ro l l  pa t ien t s  w i th  CF  who  a re  4  yea r s  o f  age  o r  o lde r  w i thou t  an  uppe r  
age  l im i t .  S ince  med ian  p red i c ted  su r v i va l  age  fo r  pa t ien t s  w i th  CF  i s  app rox ima te ly  40  
yea r s ,  i t  i s  expec ted  tha t  the  ma jo r i ty  o f  pa t ien t s  en ro l led  w i l l  be  les s  than  40  yea r s  o ld .   
 
To  ob ta in  a  d i ve r se  age  range  in  the  s tudy  popu la t ion ,  the  P I s  w i l l  be  encou raged  to  
rec ru i t  pa t ien t s  a long  the  age  con t inuum .  S ince  s tudy  s i tes  a re  ped ia t r i c  cen te r s ,  i t  i s  
expec ted  tha t  the  ma jo r i ty  o f  sub jec t s  w i l l  be  in  the  ped ia t r i c  age  range .  Howeve r ,  P I s  
a t  s tudy  s i tes  w i l l  be  encou raged  to  co l labo ra te  w i th  a f f i l ia ted  adu l t  CF  cen te r s  to  a l low  
fo r  the  rec ru i tmen t  o f  adu l t  pa t ien t s  w i th  CF .  
 
Sub jec t s  d i s con t inu ing  s tudy  pa r t i c ipa t ion  may  need  to  be  rep laced  to  ach ieve  the  
m in imum  to ta l  n umbe r  o f  30 .  A l l  ava i lab le  da ta  fo r  sub jec t s  who  we re  en ro l led  and  
d i s con t inued  w i l l  be  cap tu red  in  da ta  repo r t s .  Pa t ien t s  who  pa r t i c ipa ted  in  P ro toco l  
0000497  and  cons ide red  to  be  p ro toco l  comp l ian t  w i l l  be  e l ig ib le  fo r  en ro l lmen t  in  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368831]  th ree  pe r iods :  a  [ADDRESS_368832] ing  to  s chedu le . Howeve r ,  changes  in  
s chedu led  s tudy  v i s i t s  a re  a l lowed  w i th  pe rm i s s ion  f rom  the  s i te  fo r  ho l iday s ,  vaca t ions ,  
e t c .  Fo r  these  ex cep t ions ,  the  s tudy  v i s i t  shou ld  oc cu r  w i th in  4  day s  (4 )  o f  the  
s chedu led  day .  The re  w i l l  be  f i ve  s tudy  v i s i t s  as  des c r ibed  be low : 
 
V is i t  1 :   S tudy  En t ry  (Day  -14 ) 
 
On  V i s i t  1  ( Day  -14 ) ,  sub jec t s  (o r  lega l ly  au tho r i zed  pa ren t  o r  gua rd ian )  w i l l  s ign  a  
w r i t ten  in fo rmed  consen t , o r  as sen t  when  app l icab le .  Base l ine  p rocedu res  w i l l  inc lude  
eva lua t ion  o f  e l ig ib i l i ty  c r i te r ia  and  reco rd ing  o r  ob ta in ing  demog raph i c s ,  med i ca l  
h i s to r y ,  phy s i ca l  exam ina t ion ,  he igh t ,  we igh t ,  body  mas s  index ,  v i ta l  s igns ,  s tanda rd  
c l in i ca l  labo ra to r y  tes t s  (hema to logy ,  c l in i ca l  chem i s t r y ,  u r ina ly s i s ) ,  b lood  l ip ids ,  u r ine  
samp le  fo r  u r ina r y  leuko t r iene  eva lua t ion ,  p lasma  fa t ty  ac id  samp le ,  p regnanc y  tes t  fo r  
ch i ldbea r ing  fema les  and  concom i tan t  med i ca t ions .   Co l lec ted  resu l t s  on  Day  -[ADDRESS_368833] rage  da i l y  PERT  use  w i th  mea l s  and  snac k s  and  w i th  en te ra l  nu t r i t ion  w i l l  be  
reco rded .  S tudy  s ta f f  w i l l  p rov ide  de ta i led  ins t ruc t ions  fo r  sub jec t s  to  ma in ta in  a  
gas t ro in tes t ina l  symp tom  d ia r y  fo r  7  consecu t i ve  day s .  
 
Du r ing  the  obse r va t ion  pe r iod  (Day  -14  to  Da y  -8 ) ,  sub jec t s  w i l l  ma in ta in  the i r  usua l  
ca re  p lan .  The  b rand ,  vo lume ,  and  adm in i s t ra t ion  ra te  o f  the  en te ra l  fo rmu la  used  in  
the  en te ra l  feed ing  w i l l  be  reco rded ,  a long  w i th  the  usua l  dose  o f  PERT  use  as soc ia ted  
w i th  the  en te ra l  feed ing .  C rush ing  o f  PERT  p roduc t s  and  add ing  to  the  en te ra l  feed ing  
bag  i s  p roh ib i ted .  Sub jec t s  w i l l  make  en t r ies  in to  a  7-day  gas t ro in tes t ina l  symp tom  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  24  o f  47  d ia r y  each  day .  PERT  use  w i th  mea l s  and  snack s  and  w i th  en te ra l  tube  feed ing  w i l l  be  
reco rded  each  day  by  [CONTACT_301853] t . 
 
Du r ing  the  run  in  pe r iod  (Day  -7  to  Day  -1 ) ,  sub jec t s  w i l l  ma in ta in  the i r  usua l  en te ra l  
feed ing  vo lume  up  to  a  max imum  vo lume  o f  1000  mL  and  adm in i s t ra t ion  ra te  us ing  
Pep tamen  1 .5  fo r  a t  leas t  5  day s  p reced ing  the  t rea tmen t  pe r iod  be tween  Day  -7  and  
Day  -1.  The  usua l  dose  o f  PERT  use  as soc ia ted  w i th  the  en te ra l  feed ing  w i l l  be  
a l lowed , bu t  c rush ing  o f  PERT  p roduc t s  and  add ing  to  the  en te ra l  feed ing  bag  i s  
p roh ib i ted .  Sub jec t s  w i l l  make  en t r ies  in to  a  7 -day  gas t ro in tes t ina l  symp tom  d ia ry  each  
day .  PERT  use  w i th  mea l s  and  snac k s  and  w i th  en te ra l  tube  feed ing  w i l l  be  reco rded  
each  day  by  t he  sub jec t . Pep t amen  1 .5  fo r  use  du r ing  the  run  in  pe r iod  w i l l  be  sh ipped  
to  the  sub jec t ’s  home  p r io r  to  Day  -7 .  
V is i t  2:  Base l ine  (Day  0) 
 
Du r ing  Vi s i t  2,  as  we l l  as  each  subsequen t  v i s i t ,  the  s tudy  s t a f f  w i l l  co l lec t  the  
comp le ted  gas t ro in tes t ina l  symp to m  d ia ry .  Blood  samp le s w i l l  be  co l lec ted  fo r  fa t ty  
ac id ,  p ro te in ,  and  fa t -so lub le  v i tam in  ana ly s i s  du r ing  these  v i s i t s .  In  add i t ion ,  a  u r ine  
samp le  w i l l  be  co l lec ted  fo r  u r ina r y  leuko t r iene  ana l y s i s .  Body  we igh t  and  he igh t  w i l l  be  
measu red  and  reco rded ,  an d  BM I  w i l l  be  ca l cu la ted  and  reco rded .  Each  sub jec t  and /o r  
pa ren t ( s )  w i l l  rece i ve  ve rba l  ins t ruc t ions  on  the  tempe ra tu re  s to rage ,  se tup  and  
ope ra t ion  o f  Re l i zo rb  w i th  Impac t  Pep t ide  1 .5 .  S tudy  s ta f f  w i l l  phy s i ca l ly  demons t ra te  
se t up  and  ope ra t ion  o f  Re l i zo rb  so  tha t  sub jec t s /pa ren t s  rece i ve  hands -on  t ra in ing  p r io r  
to  leav ing  the  c l in i c . S tudy  s ta f f  w i l l  ins t ruc t  sub jec t s /pa ren t s / ca reg i ve r s  on  reco rd ing  
the  use  o f  Re l i zo rb  be tween  s tudy  v i s i t s . Sub jec t s  and  pa ren t s  w i l l  have  the  oppo r tun i t y  
to  as k  ques t ions  to  ensu re  fam i l ia r i ty  w i th  the  p r inc ip les  o f  ope ra t ion .  Th i s  w i l l  ensu re  
tha t  sub jec t s /pa ren t s  a re  know ledgeab le  rega rd ing  the  p rope r  use  o f  fo rmu la  w i th  
e i the r  the  Co v id ien  Kanga roo ™  ePump  o r  MOOG  En te ra l  L i te ® In f in i ty ® pumps .  
Ins t ruc t ions  Fo r  Use  (IFU )  w i l l  be  p rov ided  to  sub jec t s /pa ren t s  to  take  home .   
 
Impac t  Pep t ide  1 .5  i s  the  on ly  en te ra l  fo r mu la  a l lowed  fo r  use  fo r  en te ra l  tube  feed ings  
in  th i s  pa r t  o f  the  s tudy .  Sub jec t s  w i l l  ma in ta in  the i r  usua l  en te ra l  feed ing  vo lume  up  to  
a  max imum  vo lume  o f  1000  mL  and  adm in i s t ra t ion  ra te  us ing  Impac t  Pep t ide  1 .5 .   
S tudy  s ta f f  w i l l  in fo rm  sub jec t s /pa ren t s  tha t  any  use  o f  PERT  in  as soc ia t ion  w i th  the  
en te ra l  tube  feed ing  i s  s t r i c t ly  p roh ib i ted .  
 
On  o r  be fo re  Day  0,  a l l  sub jec t s  w i l l  rece i ve  ou tpa t ien t  s tudy  supp l ies ,  such  as  the  
Re l i zo rb  inves t iga t iona l  dev i ce ,  Impac t  Pep t ide  1 .5 , Re l i zo rb  A c coun tab i l i ty  Log ,  7 -day  
gas t ro in tes t ina l  d ia ry  and  spec i f i c  w r i t ten  ins t ruc t ions .  Sub jec t s /pa ren t s / ca reg i ve r s  w i l l  
be  in fo rmed  tha t  they  shou ld  s ta r t  a  7 -day  gas t ro in tes t ina l  d ia ry  one  week  be fo re  the  
nex t  s tudy  v i s i t  so  i t  i s  comp le ted  the  day  be fo re  the  nex t  s tudy  v i s i t .  Sub jec t s  w i l l  be  
ins t ruc ted  to  ma in ta in  the i r  no rma l  CF  t rea tmen t  reg imen  and  usua l  d ie t  th roughou t  the  
s tudy .  No  d ie ta r y  res t r i c t ions  ex i s t  du r ing  the  ou tpa t ien t  pe r iod .  Sub jec t s  shou ld  fo l low  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  25  o f  47  d ie ta r y  recommenda t ions  f rom  the i r  reg i s te red  d ie t i t ian  ( RD ),  nu t r i t ion i s t  o r  hea l thca re  
p ro fes s iona l .  
 
V is i t s 3,  4,  and  5 :  T rea tmen t  Pe r iod  (Day s  30 ,  60 ,  and  90 ) 
 
App rox ima te l y  o ne  week  be fo re  v i s i t s  3 ,  4 ,  and  5 ,  s tudy  s ta f f  w i l l  con tac t  
sub jec t s /pa ren t s / ca reg i ve r s  and  rem ind  them  to  s ta r t  a  7 -day  gas t ro in tes t ina l  d ia r y  
such  tha t  i t  i s  comp le ted  the  day  be fo re  the  s tudy  v i s i t ,  and  a l so  rem ind  them  to  b r in g  
the  comp le ted  d ia r y  w i th  them  to  the  c l in i c  v i s i t  a long  w i th  a l l  used  and  unused  Re l i zo rb  
ca r t r idges .  Du r ing  these  v i s i t s  s tudy  s ta f f  w i l l  co l lec t  the  comp le ted  7 -day  
gas t ro in tes t ina l  symp tom  d ia r y .  B lood  samp le s w i l l  be  co l lec ted  fo r  fa t t y  ac id ,  p ro te in ,  
and  fa t -so lub le  v i tam in  ana l y s i s  du r ing  these  v i s i t s .  In  add i t ion ,  a  u r ine  samp le  w i l l  be  
co l lec ted  fo r  u r ina ry  leuko t r iene  ana l y s i s .  Body  we igh t  and  he igh t  w i l l  be  measu red  and  
reco rded ,  and  BM I  w i l l  be  ca l cu la ted  and  reco rded .  S tudy  s ta f f  w i l l  as ses s  UADE s  and  
concom i tan t  p rocedu res  and  med i ca t ion  use .   
 
S tudy  s ta f f  w i l l  rev iew  the  Re l i zo rb  A c coun tab i l i ty  Log  fo r  comp le tenes s ,  co l lec t  a l l  
used  Re l i zo rb  ca r t r idges ,  and  p ro v ide  sub jec t s  w i th  add i t iona l  unused  Re l i zo rb  
ca r t r idges  fo r  a t  home  use  un t i l  the  nex t  s chedu led  v i s i t .  Concom i tan t  med i ca t ions  and  
UADE s  w i l l  be  as ses sed .   
 
Sub jec t s  who  expe r ienced  a  new  o r  ongo ing  UADE  w i th in  the  p rev ious  29  day s  w i l l  
rece i ve  a  fo l low -up  sa fe ty  con tac t  un t i l  30  day s  a f te r  the  oc cu r rence  o f  the  UADE  o r  
un t i l  the  UADE  has  reso l ved ,  wh i cheve r  comes  f i r s t .  The re fo re  the  du ra t ion  o f  the  
s tudy  may  be  ex tended  i f  a  sub jec t  has  a  new  o r  ongo ing  UADE  be tween  Day  60  and  
Day  90 .  
 
On  the  f ina l  c l in i c  v i s i t  ( Day  90 ),  the  ma jo r i ty  o f  base l ine  p rocedu res  w i l l  be  repea ted .  
End  o f  s t udy  p rocedu res  w i l l  inc lude  s tanda rd  labo ra to r y  tes t ing  ( c l in i ca l  chem i s t ry ,  
hema to logy  and  u r in a l y s i s ) ,  b lood  l ip ids ,  vi ta l  s ign s,  we igh t ,  and  he igh t  measu remen t ,  
and  BM I  ca l cu la t ion . 
 
Sub jec t s  w i l l  be  ins t ruc ted  to  b r ing  to  the  c l in i c  a l l  used  and  unused  de v i ce s  to  enab le  
s tudy  s ta f f  to  chec k  adm in i s t ra t ion  comp l iance .  A l l  u sed  and  u nused  ca r t r idges  w i l l  be  
inven to r ied  and  re tu rned  to  the  Spo nso r ,  un les s  des t ruc t ion  a t  the  s tudy  s i te  i s  
au tho r i zed .   
 
 Se lec t ion  o f  Pa t ien ts  
 Inc lus ion  C r i te r ia  
 
Each  pa t ien t  mus t  mee t  a l l  o f  the  fo l low ing  inc lus ion  c r i te r ia  to  be  en ro l led  in  the  s tudy :  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  26  o f  47  1 .  Ma le  o r  fema le  pa t ien t s  4  yea r s  o f  age  o r  o lde r  
2 .  Con f i rmed  d iagnos i s  o f  CF  de f ined  as  two  c l in i ca l  fea tu res  cons i s ten t  w i th  CF  
and  ha ve  e i the r :  
a .  Geno t ype  w i th  two  iden t i f iab le  mu ta t ions  cons i s ten t  w i th  CF ,  de te rm ined  
us ing  d iagnos t i c  dev i ces  tha t  have  been  c lea red  by  [CONTACT_301854]  ( the  FDA  
c lea rance  requ i remen t  does  no t  app l y  i f  the  tes t  was  pe r fo rmed  p r io r  to  
2005 ,  the  yea r  the  US  FDA  f i r s t  s ta r ted  eva lua t ing  gene t i c  tes t s  fo r  CF ) ,  o r  
b .  Swea t  ch lo r ide  >60  mEq /L  by  [CONTACT_301855] t i ta t i ve  p i loca rp ine  ion topho res i s  
3 .  Documen ted  h i s to r y  o f  exoc r ine  panc rea t i c  insu f f i c ienc y  due  to  CF  (e .g . ,  
h i s to r i ca l  feca l  e las tase  tes t ,  geno type  cons i s ten t  w i th  exoc r ine  panc rea t i c  
insu f f i c ienc y ,  e t c . )  
4 .  En te ra l  fo rmu la  use r  a  m in imum  o f  fou r  to  f i ve  t imes  pe r  week ,  us ing  PERT ,  
consum ing  an  un res t r i c ted  fa t  d ie t ,  and  w i l l ing  to  use  Pep tamen  1 .5  and  Impac t  
Pep t ide  1 .5  
5 .  C l in i ca l ly  s tab le  w i th  no  s ign i f i can t  changes  in  hea l th  s ta tus  w i th in  14  day s  o f  
Day  -14   
6 .  W r i t ten  in fo rmed  consen t  ob ta ined  f rom  pa t ien t , o r ,  i f  the  pa t ien t  i s  a  m ino r ,  f rom  
the  pa t ien t ’s  lega l  rep resen ta t i ve  w i th  as sen t  f rom  the  m ino r  when  app l i cab le . 
 
 E x c lus ion  C r i te r ia  
 
Each  pa t ien t  who  mee t s  any  o f  the  fo l low ing  ex c lus ion  c r i te r ia  w i l l  be  e x c luded  f rom  the  
s tudy : 
 
1 .  Uncon t ro l led  d iabe tes  me l l i tus  
2 .  S igns  and  s ymp tom s  o f  l i ve r  c i r rhos i s  o r  po r ta l  hype r tens ion  (e .g . ,  
sp lenomega l y ,  as c i tes ,  esophagea l  va r i ces )  o r  s ign i f i can t  l i ve r  d i sease .  
S ign i f i can t  l i ve r  d i sease  i s  de f ined  as  l i ve r  t ransam inases  >3x  uppe r  l im i t  o f  
no rma l  (ULN )  o r  to ta l  b i l i rub in  [ADDRESS_368834]  a t  base l ine  (o r  based  upon  the  
d i s c re t ion  o f  the  P r inc ipa l  Inves t iga to r  (P I )  
3 .  Lung  o r  l i ve r  t ransp lan t  
4 .  A c t i ve  cance r  d i sease  cu r ren t l y  rece i v ing  cance r  t rea tmen t  
5 .  Known  sma l l  in t es t ina l  in f lamma to r y  d i seases  such  as  C rohn ’s  o r  Ce l iac  
d i sease , o r  d ia r rhea l  i l lnes s  un re la ted  to  EP I  (e .g . ,  in fec t ious  gas t roen te r i t i s ,  
sp rue ,  lac tose  in to le rance ,  in f lamma to r y  bowe l  d i sease )  
6 .  H i s to r y  o f  f ib ros ing  co lonopa thy  o r  recu r r ing  d i s ta l  in t es t ina l  obs t ruc t i ve  
s ynd rome  (e .g .  mo re  than  th ree  oc cu r rences  pe r  yea r )  
7 .  CF  resp i ra to r y  exace rba t ions  w i th in  2  week s  p r io r  to  s tudy  en t ry  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  27  o f  47  8 .  O ra l  g lucoco r t i co id  the rapy  o r  in t ravenous  g lucoco r t i co ids  w i th in  2  week s  p r io r  
to  base l ine ;  pa t ien t s  who  a re  rece i v ing  low  dose  a l te rna te  day  co r t i cos te ro id  
the rapy  fo r  lung  d i sease  may  be  en ro l led  in  the  s tudy  sub jec t  to  consu l ta t ion  
be tween  the  s i te  P I  and  the  A l c res ta  Ch ie f  Med ica l  O f f i ce r  
9 .  Ma jo r  su rge r y  o r  se r ious  lung  in fec t ion  w i th in  2  wee k s  p r io r  to  s tudy  en t ry  
10 .  A cu te  l i fe -th rea ten ing  o r  uncon t ro l led  med i ca l  i l lnes s  
11 .  Known  a l coho l ,  d rug  o r  med i ca t ion  abuse  
12 .  Any  cond i t ion ,  in  the  judgmen t  o f  the  s i te  P I ,  wh i ch  wou ld  in te r fe re  w i th  the  
in ten t  o f  the  s tudy  o r  make  pa r t i c ipa t ion  no t  in  the  bes t  i n te res t  o f  the  pa t ien t  
13 .  Fo r  fema les  o f  ch i ldbea r ing  po ten t ia l :   
a .  Pos i t i ve  p regnanc y  tes t  a t  s tudy  en t ry  
b .  Lac ta t ing  
c .  Unw i l l ing  to  use  an  e f fec t i ve  med i ca l ly  ac cep tab le  fo rm  o f  con t racep t ion  
(e .g . ,  p res c r ip t ion  o ra l  con t racep t i ves ,  con t racep t i ve  in jec t ions ,  
con t racep t i ve  pa t ch ,  an  in t rau te r ine  de v i ce ,  NuVaR ing ®,  d iaph ragm  w i th  
spe rm i c ide  o r  abs t inence )  f rom  base l ine  to  the  end  o f  the  s tudy .  
14 .  T rea tmen t  w i th  inves t iga t iona l  s tudy  a gen t s  (d rug ,  b io log i c  o r  dev i ce )  o the r  than  
Re l i zo rb  w i th in  [ADDRESS_368835]  
oc cu r red  in  wh i ch  the  pa t ien t  no  longe r  mee t s  the  in i t ia l  e l ig ib i l i ty  c r i te r ia .  A l l  e l ig ib le  
pa t ien t s  w i l l ing  to  con t inue  in  th i s  s tudy  w i l l  be  a c cep ted .  E ve r y  reasonab le  a t temp t  
shou ld  be  made  by  s tudy  s ta f f  to  as s i s t  e l ig ib le  pa t ien t s  in te res ted  in  pa r t i c ipa t ing  in  
th i s  s tudy .  
 
Any  sub jec t  who  w i thd raw s  f rom  the  s tudy  be fo re  S tudy  V i s i t  3  on  Day  30  w i l l  be  
rep laced  by  [CONTACT_1629]  e l ig ib le  pa t ien t .   
 
Any  sub jec t  who  w i thd raw s  f rom  the  s tudy  be fo re  S tudy  V i s i t  4  on  Day  60  mus t  be  
rep laced  by  [CONTACT_1629]  e l ig ib le  pa t ien t .   
 
Any  sub jec t  who  w i thd raw s  f rom  the  s tudy  be fo re  S tudy  V i s i t  5  on  Day  90  may  be  
rep laced  by  [CONTACT_1629]  e l ig ib le  pa t ien t  un les s  the  sum  o f  comp le te d  sub jec t s  and  cu r ren t ly  
en ro l led  and  ac t i ve  sub jec t s  i s  g rea te r  than  30 ,  in  wh i ch  case  the  sub jec t  w i l l  no t  be  
rep laced  un les s  the  sum  o f  comp le ted  sub jec t s  and  cu r ren t ly  en ro l led  and  ac t i ve  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368836] .  
 
 A l lowed  Concom i tan t  Med ica t ions  
Sub jec t s  shou ld  con t inue  a l l  p res c r ibed  med i ca t ions  and  suppo r t i ve  the rap ies .  
Concom i tan t  med i ca t ions  t aken  fo r  cu r ren t  med i ca l  h i s to r y  and  b i r th  con t ro l  a re  a l l  
a l lowed .  P res c r ip t ion  and  ove r -the -coun te r  med i ca t ions  fo r  the  t rea tmen t  o f  AE / UADE s  
a re  pe rm i t ted . 
 
A l l  suppo r t i ve  the rap ies  and  concom i tan t  med i ca t i ons  taken  by  [CONTACT_301853] t  w i l l  be  
reco rded  in  the  sou r ce  documen t s  and  en te red  on  the  e lec t ron i c  case  repo r t  fo rm  
(eCRF ) .  Any  dosage  changes  to  concom i tan t  med i ca t ions  requ i red  du r ing  the  s tud y  
mus t  be  reco rded  in  the  eCRF .  
 
 P roh ib i ted  Med ica t ions  
The re  a re  cu r ren t ly  no  known  i n te rac t ions  to  o t he r  med i ca t ions  w i th  Re l i zo rb .  
T rea tmen t s w i th  any  inves t iga t iona l  d rug ,  b io log i c  o r  med i ca l  dev i ce  a re  p roh ib i ted  
du r ing  the  s tudy .   
 
Sub jec t s  may  use  o ra l  PERT  w i th  mea l s  and  snac k s  du r ing  the  day  bu t  a re  p roh ib i ted  
f rom  us ing  PERT  o r  any  o the r  med i ca t ion  in tended  to  hyd ro ly ze  fa t  i f  as soc ia ted  w i th  
adm in i s t ra t ion  o f  en te ra l  tube  feed ing .   
 
 Sa fe ty  Mon i to r ing   
 S tudy  Sa fe ty  P rocedu res  
 
Sa fe t y  da ta  w i l l  be  mon i to red  on  a  con t inua l  bas i s  th roughou t  the  s tudy  and  c l in i ca l  
changes  eva lua ted .  Sa fe t y  mon i to r ing  w i l l  inc lude  sa fe t y  fo l low -up  con tac t s ,  mon i to r ing  
AE /UADE ,  sub jec t  w i thd rawa l s  and  sa fe t y  da ta .  The  s i te  mon i to r  w i l l  adv i se  the  Ch ie f  
Med i ca l  O f f i ce r  o f  the  f requenc y  and  seve r i t y  o f  UADE s .  The  A l c res ta  Ch ie f  Med i ca l  
O f f i ce r  w i l l  eva lua te  a l l  UADE s  w i th in  24  hou r s  o f  no t i f i ca t ion .    
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  29  o f  47   S tudy  P rocedu res  
Tab le  1  l i s t s  the  t im ing  o f  as ses smen t s  and  s tudy  p rocedu res . I f  a  sub jec t  m i s ses  a  
s c hedu led  s tudy  v i s i t  w i th in  the  ±4  day  w indow ,  the  v i s i t  shou ld  be  res chedu led  a s  
soon  as  pos s ib le .  
 
 In fo rmed  Consen t  
 
Each  pa t ien t  mus t  p ro v ide  w r i t ten  in fo rmed  consen t ,  as  we l l  as  as sen t ,  when  
app l i cab le ,  be f o re  any  s tudy -re la ted  p rocedu re  i s  conduc ted .  
 
 Inc lus ion  and  E x c lus ion  C r i te r ia  
 
The  inc lus ion  and  ex c lus ion  c r i te r ia  w i l l  be  rev iewed  to  de te rm ine  pa t ien t  e l ig ib i l i ty .  
 
 Demog raph i c s  
 
Sub jec t  demog raph i c s  w i l l  documen t  age ,  gende r ,  and  e thn i c i ty . 
 
 Med i ca l  H i s to ry  
 
On  Day  -14 ,  a  re levan t  med i ca l  h i s to ry  da t ing  bac k  a t  leas t  1  yea r  w i l l  be  ob ta ined .  The  
med i ca l  h i s to ry  w i l l  emphas i ze  CF  d i sease  cha rac te r i s t i c s ,  p r io r  the rapy ,  su rge r y ,  
a l le rg ies  and  as ses s  the  pa t ien t  fo r  any  d i squa l i f y ing  med i ca l  cond i t ions  as  spec i f ied  in  
the  ex c lus ion  c r i te r ia .  
 
 Phy s i ca l  E xam ina t ion  
 
Comp le te  phy s i ca l  exam ina t ions  a re  requ i red  fo r  a l l  pa t ien t s  en te r ing  the  s tudy .  A 
qua l i f ied  membe r  o f  the  s tudy  s ta f f  (e .g . ,  phy s i c ian ,  phy s i c ian ’s  as s i s tan t )  w i l l  pe r fo rm  a  
comp le te  phy s i ca l  exam ina t ion .   
 
 He igh t ,  We igh t , and  BM I  
 
He igh t ,  we igh t  and  BM I  w i l l  be  as ses sed  a t  the  t ime  po in t s  ou t l ined  in  Tab le  1. In  
add i t ion ,  s tudy  s ta f f  w i l l  rev iew  the  med i ca l  reco rd  and  reco rd  up  to  4  body  we igh t s a t  3  
mon th  in te r va l s  reco rded  o ve r  the  p re v ious 12  mon ths .  
 
 V i ta l  S igns  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  30  o f  47  A f te r  a  m in imum  res t ing  pe r i od  o f  15  m inu tes ,  v i ta l  s igns  ( hea r t  ra te ,  resp i ra to r y  ra te  
and  s i t t ing  b lood  p res su re )  w i l l  be  measu red .  Ora l  o r  tympan i c  tempe ra tu re  w i l l  a l so  be  
co l lec ted .   
 
 C l in i ca l  Labo ra to r y  Tes t s  
 
B lood  samp le  co l lec t ions  w i l l  be  ob ta ined  a t  the  t ime  po in t s  ou t l ined  in  Tab le  1. 
Sub jec t s  w i l l  be  in  a  sea ted  o r  sup ine  pos i t ion  du r ing  b lood  samp le  co l lec t ion .   
 
The  c l in i ca l  labo ra to r y  tes t s  to  be  pe r fo rmed  a re  l i s ted  in  Tab le  2  (C l in i ca l  Labo ra to r y  
Tes t s )  be low . Hand l ing  and  sh ipmen t  o f  c l in i ca l  labo ra to r y  samp les  w i l l  be  ana l y zed  by  
a  cen t ra l  labo ra to r y  and  be  ou t l ined  in  the  labo ra to r y  manua l .  
 
 P regnanc y  Tes t  
 
A  se rum  β -hCG  p regnanc y  tes t  w i l l  be  pe r fo rmed  on l y  fo r  fema les  o f  ch i ldbea r ing  
po ten t ia l .  Nega t i ve  resu l t s  mus t  be  a va i lab le  fou r  day s  p r io r  to  the  f i r s t  Re l i zo rb  usage  
on  Day  0.  I f  a  fema le  sub jec t  becomes  p regnan t  wh i le  pa r t i c ipa t ing  in  the  s tudy ,  the  
s i te  i s  respons ib le  fo r  no t i fy ing  the  A l c res ta  Ch ie f  Med i ca l  O f f i ce r  as  soon  as  pos s ib le .  
 
 En te ra l  Tube  Feed ing  
 
Du r ing  the  t rea tmen t  pe r iod  (Day s  0  to  90 ) ,  sub jec t s  w i l l  rece i ve  en te ra l  feed ings  us ing  
the  same  en te ra l  fo rmu la , Impac t  Pep t ide  1 .5 .  The  vo lume  o f  en te ra l  tube  feed ing  
shou ld  be  500  to  1000  mL ;  sub jec t s  who  rou t ine l y  rece i ve  mo re  o r  les s  vo lume  may  be  
en ro l led  on l y  i f  app ro ved  by  [CONTACT_941]  A l c res ta  Ch ie f  Med i ca l  O f f i ce r .  The  en te ra l  fo rmu la  
shou l d  be  de l i ve red  us ing  a  compa t ib le  pump  tha t  has  a  no  f low / low  f low  a la rm  a t  a  
f low  ra te  se t  be tween  24  and  120  mL .  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  31  o f  47  Tab le  2:  C l in ica l  Labo ra to ry  Tes ts  
C l in ica l  Chem is t ry  Hema to logy  L ip ids  U r ina lys is  
A lbum in  Comp le te  b lood  coun t  
and  wh i te  b lood  ce l l  
d i f fe ren t ia l  To ta l  c ho les te ro l  B i l i rub in  
A l ka l ine  phospha tase  T r ig l y ce r ides  Ke tones  
ALT  HDL  Leu ko cy te  es te rase  
AST   LDL  pH  
B i ca rbona te    P ro te in  
BUN    Spe c i f i c  g rav i ty  
Ca l c ium    U r ina ry  c rea t in ine  
Ch lo r ide    U r ina ry  u r i c  a c id  
Cho les te ro l     
C rea t ine  phospho k inase     
C rea t in ine     
G lu cose     
La c ta te  deh yd rogenase     
Magnes ium     
Phospho ru s     
Po ta s s ium     
P rea lbum in     
Sod ium     
To ta l  and  d i re c t  b i l i rub in     
To ta l  p ro te in     
U r i c  a c id     
A1C  leve l s     
T ran s fe r r in     
 
 Gas t ro in tes t ina l  Symp tom  D ia ry  
 
De ta i led  ve rba l  ins t ruc t ions  on  how  to  reco rd  en t r ies  in  the  gas t ro in tes t ina l  symp tom  
d ia r y  shou ld  be  conduc ted  by  s tudy  s ta f f  on  Day  -14  and  aga in  as  a  subsequen t  
rem inde r  on  Day s 0 ,  30 ,  and  60 .  The  gas t ro in tes t ina l  symp tom  d ia r y  w i l l  a l so  inc lude  a  
b r ie f  ins t ruc t ion .   En t r ies  need  to  oc cu r  on  a  da i ly  bas i s  fo r  7  consecu t i ve  day s .  The  
comp le ted  s ymp tom  d ia r y  w i l l  be  en te red  in to  the  eCRF  and  rega rded  as  a  sou r ce  
documen t .   D ia ry  d a ta  w i l l  be  used  fo r  th e  p r ima r y  sa fe ty  s tudy  endpo in t  to  de te rm ine  
the  f requenc y  and  se ve r i t y  o f  gas t ro in tes t ina l  symp tom s .    
  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  32  o f  47   P lasma  and  T i s sue  Fa t ty  A c id  Samp les  
 
Blood  samp le s w i l l  be  co l lec ted  on  Day  -14  and  Day  0  as  base l ine  measu re s o f  fa t t y  
ac id  leve l s .  The  o the r  fa t ty  ac id  b lood  samp les  w i l l  be  ob ta ined  a t  the  t ime  po in t s  
spec i f ied  in  Tab le  1. 
 
 Fa t  So lub le  V i tam in  Samp les  
 
Blood  samp le s w i l l  be  co l lec ted  on  Day  -14  and  Day  0  to  measu re  base l ine  fa t -so lub le  
v i tam in  (A ,  D ,  and  E )  leve l s .  The  o the r  fa t -so lub le  v i tam in  b lood  samp les  w i l l  be  
ob ta ined  a t  the  t ime  po in t s  spec i f ied  in  Tab le  1. 
  
 Se rum  P ro te in  Samp les  
 
Blood  samp les  w i l l  be  co l lec ted  on  Day  -14  and  Day  0  as  base l ine  measu res  o f  se rum  
p ro te in  ( to ta l  p ro te in ,  p rea lbum in ,  a lbum in ,  t rans fe r r in )  leve l s .  The  o the r  se rum  p ro te in  
b lood  samp les  w i l l  be  ob ta ined  a t  the  t ime  po in ts  spec i f ied  in  Tab le  1.  
  
 Remova l  o f  Sub jec ts  f rom  the  S tudy   
Du r ing  th e  cou r se  o f  th i s  s tudy ,  sub jec t s  w i l l  be  w i thd rawn  and  the i r  pa r t i c ipa t ion  
te rm ina ted  i f  any  o f  the  fo l low ing  oc cu r s :  
• Any  UADE  seve re  enough  in  na tu re  to  wa r ran t  d i s con t inua t ion  in  the  s tudy  
• W i thd rawa l  o f  consen t  
• The  s i te  P I ,  in  consu l ta t ion  w i th  the  A l c res ta  Ch ie f  Med i ca l  O f f i ce r ,  be l ieves  the  
sub jec t  shou ld  be  remo ved  f rom  th e  s tudy  fo r  sa fe t y  reasons  
• Sub jec t  i s  non -comp l ian t  w i th  s tudy  requ i remen t s .  
 
5 .0  DATA  ACQU IS IT ION ,  TR ANSFER  AND  ANALYS IS  
 Da ta  Acqu is i t ion  
E lec t ron i c  case  repo r t  fo rm s  (eCRF )  a re  cons ide red  con f iden t ia l  da ta .  The  A l c res ta  
da ta  managemen t  vendo r  w i l l  p rov ide  use r  ac ces s  and  t ra in ing  to  inves t iga t i ve  s i tes  on  
the  use  o f  the  eCRF  s y s tem .  Sub jec t  da ta  w i l l  be  en te red  in to  the  eCRF  by  s i te  s ta f f  
us ing  a  secu re ,  web -based  e lec t ron i c  da ta  cap tu re  app l i ca t ion .  C l in i ca l  da ta  requ i red  
by  [CONTACT_941]  p ro toco l  w i l l  be  cap tu red  o n  the  eCRF  and  suppo r ted  by  [CONTACT_301856] r ce  documen ta t ion  
a t  s i te .  The  s i te  P I  w i l l  p repa re  and  ma in ta in  adequa te  and  ac cu ra te  med i ca l  h i s to r ies  
des igned  to  reco rd  a l l  obse r va t ions  and  pe r t inen t  s tudy  da ta  fo r  each  sub jec t . 
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368837] ing  to  fu l ly  execu ted  da ta  
t ransm i s s ion  ag reemen t s ,  da ta  managemen t  p lans  o r  o the r  s tudy  documen ta t ion .   
 
 Ana lys is  o f  Fa t ty  Ac id  Abso rp t ion  
The  concen t ra t ion  o f  LCPUFA s  such  as  DHA  and  EPA  in  p lasma  i s  the  p r ima r y  
de te rm ina t ion  suppo r t ing  the  p r ima r y  endpo in t  o f  fa t  abso rp t ion  and  w i l l  be  ana ly zed  
us ing  UPLC -MS  exp res sed  as  ug /mL .  The  re la t i ve  leve l s  o f  LCPUFA s  such  as  DHA  
and  EPA  in  e ry th roc y te  memb rane  and  the  ove ra l l  p lasma  fa t ty  ac id  p ro f i le  a l so  
suppo r t  the  p r ima r y  endpo in t  and  w i l l  be  ana l y zed  us ing  GC /MS  exp res sed  as  g /100  g  
FA .   
 
6 .0  SAFETY  OVERV IEW  
 Mon i to r ing  o f  Adve rse  Even ts  
A l l  s tudy  s ta f f  a re  respons ib le  fo r  ensu r ing  tha t  comp le te  sa fe ty  da ta  has  been  
reco rded  on  the  eCRF .  Med i ca l  as ses smen t s  mus t  be  pe r fo rmed  du r ing  each  
s chedu led  s tudy  v i s i t  and  se r ve  as  the  p r ima r y  bas i s  fo r  iden t i fy ing  an  UADE .  A l though  
spon taneous  o r  e l i c i ted  med i ca l  comp la in t s  w i l l  l i k e ly  cons t i tu te  the  ma jo r i ty  o f  UADE s ,  
any  non -s chedu led  v i s i t  to  a  h ea l thca re  p ro v ide r , o r  the  in i t ia t ion  o f  a  new  med i ca t ion , 
shou ld  t r igge r  add i t iona l  ques t ion ing  as  to  the  oc cu r rence  o f  an  A E o r  UADE . 
 
 Adve rse  Even ts  
An  adve r se  expe r ience  ( AE ) i s  de f ined  as  any  un towa rd  med i ca l  oc cu r rence  in  a  
sub jec t , rega rd les s  o f  i t s  causa l  re la t ionsh ip  to  the  inves t iga t iona l  dev i ce .  An  AE  can  
the re fo re  be  any  un fa vo rab le  and  un in tended  s ign  ( inc lud ing  abno rma l  labo ra to r y  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  34  o f  47  f ind ings ) ,  symp tom  o r  d i sease  expe r ienced  w i th  use  o f  the  p roduc t ,  whe the r  o r  no t  i t  i s  
re la ted  to  the  p roduc t .  Th i s  inc ludes  any  new ly  oc cu r r ing  e ven t  o r  a  p re v ious  cond i t ion  
tha t  has  inc reased  in  seve r i t y  o r  f requenc y  s ince  the  use  o f  Re l i zo rb . 
 
 Causa l  Re la t ionsh ip  
 
A l l  AE  mus t  be  as ses sed  fo r  causa l i ty  in  re fe rence  to  Re l i zo rb  use .  When  en te r ing  d a ta  
fo r  a  repo r ted  AE ,  the  s i te  P I  w i l l  be  as ked  to  as ses s  the  re la t ionsh ip  o f  Re l i zo rb  use  to  
the  AE .  Causa l i ty  w i l l  be  ca tego r i zed  ac co rd ing  to  the  fo l low ing  c r i te r ia :  
 
No t  Re la ted :   The re  i s  no  m ed i ca l  ev idence  to  sugges t  the  e ven t  may  be  
 re la ted  to  Re l i zo rb  use ,  o r  the re  i s  ano the r  mo re  p robab le  
 med i ca l  exp lana t ion .  
 
Poss ib ly  Re la ted :  An  even t ,  inc lud ing  labo ra to r y  tes t  abno rma l i ty ,  w i th  a  tempo ra l  
re la t ionsh ip  to  Re l i zo rb  use  tha t  makes  a  causa l  re la t ionsh ip  
imp robab le  and  wh i ch  o the r  med i ca t ions ,  even t s  o r  unde r l y ing  
d i sease  p ro v ide  a  p laus ib le  exp lana t ion .   
 
P robab ly  Re la ted :  The  even t  oc cu r red  w i th in  a  reasonab le  t ime  sequence  to  us ing  
Re l i zo rb , bu t  cou ld  be  exp la ined  by  [CONTACT_301857] r ren t  d i sease  o r  o the r  
med i ca t ions  o r  even t s .   
 
Re la ted :  The re  i s  s t ron g  med i ca l  ev idence  to  sugges t  tha t  the  AE  i s  re la ted  
to  Re l i zo rb  use . 
 
 An t i c ipa ted  Adve r se  E ven t s  in  Sub jec t s  
 
Due  to  the  G I  comp l i ca t ions  inhe ren t  in  CF  pa t ien t s ,  the  iden t i f ied  r i s k s  a re  uppe r  
abdom ina l  pa in ,  b loa t ing ,  cons t ipa t ion ,  d ia r rhea ,  f la tu lence ,  hea r tbu rn ,  ind iges t ion ,  
nausea ,  s tea to r rhea  ( fa t t y  s too l ) ,  vom i t ing ,  we igh t  dec rease  and  headache .  
 
 Unan t ic ipa ted  Adve rse  Dev ice  E f fec ts   
An  unan t i c ipa ted  adve r se  de v i ce  e f fec t  (UADE )  i s  any  se r ious  adve r se  e f fec t  on  hea l th  
o r  sa fe t y ,  any  l i fe -th rea ten ing  p rob lem  o r  dea th  caused  by ,  o r  as soc ia ted  w i th  a  dev i ce ,  
i f  tha t  e f fec t ,  p rob lem ,  o r  dea th  was  no t  p re v ious ly  iden t i f ied  in  na tu re ,  seve r i t y ,  o r  
deg ree  o f  inc idence  in  the  app l i ca t ion ;  o r  any  o the r  unan t i c ipa ted  se r ious  p rob lem  
as soc ia ted  w i th  a  dev i ce  th a t  re la tes  to  the  r igh t s ,  sa fe ty ,  o r  we l fa re  o f  sub jec t s .  
 
An  UADE  i s  ana logous  to  a  se r ious  adve r se  e ven t  ( SAE ) ,  de f ine d  as  any  A E, oc cu r r ing  
a t  any  exposu re  to  the  the rapeu t i c  agen t , tha t  resu l t s  in  any  o f  the  fo l low ing  ou t comes :  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  35  o f  47  dea th ,  l i fe -th rea ten ing  AE ,  inpa t ien t  hosp i ta l i za t ion  o r  p ro long ed  ex i s t ing  
hosp i ta l i za t ion ,  a  pe r s i s ten t  o r  s ign i f i can t  d isab i l i ty  o r  i ncapac i ty  o r  a  congen i ta l  
anoma l y /b i r th  de fec t .  
 
An UADE  i s  de f ined  as  “any  se r ious  ad ve r se  e f fec t  on  hea l th  o r  sa fe t y  o r  any  
l i fe -th rea ten ing  p rob lem  o r  dea th  caused  by ,  o r  as soc ia ted  w i th ,  a  dev i ce ,  i f  tha t  e f fec t ,  
p rob lem ,  o r  dea th ,  was  no t  p rev ious l y  iden t i f ied  in  a  na tu re ,  seve r i t y  o r  deg ree  o f  
inc idence  in  the  inves t iga t iona l  p lan  o r  app l i ca t ion  ( inc lud ing  a  supp lemen ta r y  p lan  o r  
app l i ca t ion ) ,  o r  any  o the r  unan t i c ipa ted  se r ious  p rob lem  as soc ia ted  w i th  a  dev i ce  tha t  
re la tes  to  the  r igh t s ,  sa fe t y ,  o r  we l fa re  o f  sub jec t s ”  ac co rd ing  to  21  C ode  o f  Fede ra l  
Regu la t ions  Pa r t  812 .3 .  
 
A s  p rov ided  by  [CONTACT_301858] t iona l  Con fe rence  o f  Ha rmon i za t ion  ( ICH )  cr i te r ia ,  a  se r ious  
ad ve r se  e f fec t  (even t )  i s  an y  c l in i ca l  even t  o r  cond i t ion  tha t  i s : 
• Fa ta l  
• L i fe -th rea ten ing  
(No te :   T he  t e rm  “ l i fe -th rea ten ing ”  re fe r s  to  any  AE  tha t ,  as  i t  oc cu r s ,  pu t s  the  
sub jec t  a t  immed ia te  r i s k  o f  d ea th .  I t  does  no t  re fe r  to  an  A E  tha t  hypo the t i ca l ly  
m igh t  have  caused  dea th  i f  i t  we re  mo re  seve re .) 
• Requ i res  hosp i ta l i za t ion  o r  p ro long ed  cu r ren t  hosp i ta l i za t ion  (no t  inc lud ing  
hosp i ta l i za t ion  fo r  a  p re -ex i s t ing  cond i t ion  tha t  has  no t  inc reased  in  se ve r i t y  o r  
f requenc y  f rom  the  sub jec t ’ s unde r l y ing  med i ca l  cond i t ion  p r io r  to  en t r y  in to  the  
s tudy )  
• Resu l t s  in  pe r s i s ten t  o r  s ign i f i can t  d i sab i l i ty / incapac i t y  
• A congen i ta l  anoma l y /b i r th  de fec t  
• Judged  to  be  med i ca l ly  s ign i f i can t  by  [CONTACT_301859] t iga to r  
(No te :   A  med i ca l ly  s ign i f i can t  A E  i s  a  med i ca l  even t  tha t  may  no t  be  immed ia te ly  
l i fe -th rea ten ing  o r  resu l t  in  dea th  o r  hosp i ta l i za t io n  bu t  may  jeopa rd i ze  the  sub jec t  
o r  requ i re  in te r ven t ion  to  p re ven t  one  o f  the  ou t comes  l i s ted  above ) .  
 
 Repo r t ing  Unan t ic ipa ted  Adve rse  Dev ice  E f fec ts  
A  sponso r  who  co nduc t s  an  e va lua t ion  o f  an  UADE  unde r  §812 .46 (b )  sha l l  repo r t  the  
resu l t s  o f  such  eva lua t ion  to  FDA  and  to  a l l  rev iew ing  IRB ' s  and  pa r t i c ipa t ing  
inves t iga to r s  w i th in  10  bus ines s  day s  a f te r  the  sponso r  f i r s t  rece i ves  no t i ce  o f  the  
UADE .  The rea f te r  the  sponso r  sha l l  subm i t  such  add i t iona l  repo r t s  conce rn ing  the  
e f fec t  as  FDA  reques t s .  The  s i te  w i l l  comp le te  an  UADE  e ven t  eCRF  fo rm  w i th in  24  
hou r s  o f  the  Inves t iga to r  be ing  no t i f ied  o f  the  UADE .  The  repo r t  w i l l  be  s canned  and  
ema i led  to  c l in i ca l@a l c res ta . com  and  then  fo rwa rded  fo r  A l c res ta  Ch ie f  Med i ca l  O f f i ce r  
rev iew .   
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  36  o f  47  In  add i t ion ,  any  even t  tha t  resu l t s  in  a  sub jec t ’s  w i thd rawa l  f rom  the  s tudy  mus t  be  
repo r ted  d i rec t l y  to  the  A l c res ta  Ch ie f  Med i ca l  O f f i ce r  as  soon  as  pos s ib le  bu t  no  la te r  
than  [ADDRESS_368838]  80%  powe r  
to  de tec t  a  m in imum  e f fec t  s i ze  o f  0 .53 .  Based  on  l i te ra tu re  rev iew s  us ing  1 .5%  as  the  
max imum  s tanda rd  de v ia t ion  expec ted  when  measu r ing  DHA  leve l s ,  the  s tudy  shou ld  
be  ab l e  to  de tec t  an  abso lu te  inc rease  o f  a t  leas t  0 .8%  f rom  the  base l ine  DHA  va lue  
a f te r  90  day s  o f  Re l i zo rb  use  ( i .e . ,  a  change  f rom  3 .0%  a t  base l ine  to  3 .8%  a f te r  90  
adm in i s t ra t ion  day s  o r  a  27%  re la t i ve  inc rease ) .  Th i s  samp le  s i ze  w i l l  be  adequa te  to  
de tec t  the  des i red  30%  re la t i ve  inc rease  in  DHA  leve l s .   
 
 S topp ing  Ru les  
 
Re l i zo rb  i s  a  low  r i s k  med i ca l  dev i ce ,  and  the  pa t ien t  popu la t ion  unde r  s tudy  i s  a t  
re la t i ve l y  low  r i s k  fo r  a  seve re  ad ve r se  expe r ien ce .  The re fo re ,  the re  a re  no  p rospec t i ve  
s topp ing  ru les  f o r  th i s  s tudy .  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368839]  (DSM B )  as  soon  as  pos s ib le  i f  any  o f  the  
fo l low ing  oc cu r :  
 
• Dea th  o f  any  sub jec t  in  the  s tudy ,  rega rd les s  o f  causa l i ty ,  
• Two  oc cu r rences  o f  the  same  UADE  whe re  causa l i ty  has  been  as s igned  to  
Re l i zo rb  use  by  [CONTACT_941]  s i te  P I ,  o r  mo re  than  th ree  oc cu r rences  o f  the  same  UADE  
rega rd les s  o f  causa l i ty ,  
• A  t rend  eme rges  in  the  oc cu r rence  o f  s im i la r  UADE s .  
 
I f  e i the r  the  A l c res ta  Ch ie f  Med i ca l  O f f i ce r  o r  the  cha i r  o f  the  DSMB  has  a  conce rn  
rega rd ing  the  sa fe t y  o f  s tudy  sub jec t s ,  the  Ch ie f  Med i ca l  O f f i ce r  w i l l  convene  a  
te lecon fe rence  w i th  the  DSMB  and  the  s i te  P I s  as  soon  as  pos s ib le  to  d i s cus s  the  
po ten t ia l  sa fe ty  i s sue .  Pos s ib le  ou t comes  o f  the  te lecon fe rence  inc lude :  
 
• Con t inua t ion  o f  the  s tudy  w i th  no  change  in  s tudy  conduc t  i f  i t  i s  de te rm ined  tha t  
the re  i s  no  sa fe ty  i s sue ,  
• P lac ing  the  s tudy  on  c l in i ca l  ho ld  un t i l  the  s tudy  p ro toco l  can  be  mod i f ied  to  
m i t iga te  the  sa fe ty  i s sue ,  
• Te rm ina t ion  o f  the  s tudy .  
 
 Random i za t ion  
Random i za t ion  w i l l  no t  be  used  in  th i s  open  labe l  s tudy . 
 
 Popu la t ions  fo r  Ana lys is  
 Pe r  P ro toco l  Popu la t ion  
The  pe r  p ro toco l  p opu la t ion  cons i s t s  o f  a l l  sub jec t s  who  me t  the  inc lus ion  c r i te r ia ,  used  
Re l i zo rb  as  s ta ted  in  the  p ro toco l  and  IFU  th rough  a t  leas t  V i s i t  3  ( Day  30 ) and  ha s  no t  
been  the  sub jec t  o f  any  ma j o r  p ro toco l  dev ia t ion .  
 
 Sa fe t y  Popu la t i on  
The  sa fe ty  popu la t ion  inc ludes  a l l  sub jec t s  who  rece i ved  a t  leas t  one  Re l i zo rb  
exposu re .  Fo r  sub jec t s  who  w i thd raw  f rom  the  s tudy ,  eve r y  e f fo r t  w i l l  be  made  to  
re t r ieve  a l l  re levan t  sa fe t y  in fo rma t ion .   
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368840] .  
 
 Demog raph ics  and  Base l ine  Cha rac te r is t ics  
Demog raph i c  and  base l ine  cha rac te r i s t i c s  w i l l  be  summa r i zed  and  p resen ted  o ve ra l l .  
Demog raph i c  da ta  to  be  e va lua ted  w i l l  inc lude  a ge ,  sex ,  e thn i c i ty ,  he igh t ,  we igh t  and  
BM I .  Demog raph i c  da ta  w i l l  be  p res en ted  in  a  by -sub jec t  l i s t ing .  Age  w i l l  be  ca l cu la ted  
f rom  da te  o f  b i r th  to  da te  in fo rme d  consen t  was  ob ta ined .   
 
 Sa fe ty  Ana lys is  
Sa fe t y  w i l l  be  as ses sed  based  on  the  inc idence ,  seve r i t y ,  and  t ype  o f  AE  and  UADE ,  
c l in i ca l ly  s ign i f i can t  changes  o r  abno rma l i t ies  in  the  sub jec t ’s  c l in i ca l  labo ra to r y  resu l t s  
and  v i ta l  s igns .  Fo r  c l in i ca l  labo ra to r y  tes t s ,  des c r ip t i ve  summa r ies  o f  ac tua l  va lues  and  
changes  f rom  t he  base l ine  w i l l  be  p resen ted .  Des c r ip t i ve  s ta t i s t i c s  w i l l  be  p rov ided  fo r  
v i ta l  s ign  measu remen t s  co l lec ted  du r ing  c l in i c  v i s i t s .  
 
AE  and  UADE s  w i l l  be  reco rded  th roughou t  the  s tudy  and  l i s ted  in  summa r y  ta b les  in  
te rm s  o f  seve r i t y  and  causa l  re la t ionsh ip  to  Re l i zo rb  use .  Re la t i onsh ip  as ses smen t s  
tha t  ind i ca te  the  AE  i s  “No t  Re la ted ”  i s  an  even t  re la ted  to  e t io logy ,  ra the r  than  f rom  
Re l i zo rb  use . “Re la ted ”  i s  de f ined  as  an  as soc ia t ion  be tween  the  AE  o r  UADE  and  
Re l i zo rb  use .  O the r  se lec t ions  inc lude  “Pos s ib ly  Re la ted ”  and  “P robab l y  Re la ted ” .  
 
The  gas t ro in tes t ina l  symp tom s  reco rded  in  the  7  day  gas t ro in tes t ina l  symp tom  d ia ry  
du r ing  the  run  in  pe r io d  w i l l  be  compa red  w i th  the  s ymp tom s  reco rded  th ree  sepa ra te  
t imes  du r ing  the  t rea tmen t  pe r iod .   Each  s ymp tom  w i l l  be  ca tego r i zed  as  a )  oc cu r r ing  
o r  no t  oc cu r r ing  b )  ra ted  as  a  1 ,2 ,  o r  3  in  seve r i ty ,  and  las t ing  in  du ra t ion  fo r  les s  than  
15  m inu tes ,  15  to  30  m inu tes ,  31  to  60  m inu tes ,  o r  g rea te r  than  60  m inu tes .  
   
Fo r  the  compa r i son  be tween  s ymp tom s  reco rded  du r ing  the  run  in  pe r iod  and  the  
t rea tmen t  pe r iod ,  the  fo l low ing  ana l y ses  w i l l  be  pe r fo rmed :  
 
• Numbe r  o f  day s  whe re  any  symp tom  oc cu r red ;  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  39  o f  47  • Numbe r  o f  day s  each  s ymp tom  oc cu r red ;  
• Fo r  each  s ymp tom ,  numbe r  o f  day s  when  the  seve r i t y  was  a  1 ,  2 ,  and  3  
• Fo r  each  s ymp tom ,  numbe r  o f  day s  when  the  s ymp tom s  las ted  in  du ra t ion  fo r  
les s  than  15  m inu tes ,  15  to  30  m inu tes ,  31  to  60  m inu tes ,  o r  g rea te r  than  60  
m inu tes .  
Co mpa r i son  o f  these  va lues  du r ing  the  run  in  and  t rea tmen t  pe r iods  w i l l  be  pe r fo rmed  
us ing  ana l y s i s  o f  va r iance  ( ANOVA ). 
 
 E f f icacy  Ana lys is  
The  measu remen t  o f  the  abso rp t ion  o f  fa t s i s  a n  impo r tan t  e f f i cac y  endpo in t ,  us ing  
abso rp t ion  o f  fa t ty  ac ids  as  su r rog a te  b ioma r ke r s  fo r  fa t  abso rp t ion .  LCPUFA  p lasma  
concen t ra t ions  such  as  DHA  and  EPA  w i l l  be  an  ou t come  va r iab le ,  a long  w i th  t i s sue  
ac c re t ion  o f  LCPUFA s ,  measu red  as  re la t i ve  leve l s  in  e ry th roc y te  memb rane ,  and  the  
p ro f i le  o f  fa t ty  ac ids  in  p lasma .  The  fa t ty  ac id  p ro f i le  w i l l  a l so  be  used  to  ca l cu la te  the  
ra t io  o f  omega -6  to  omega -3  fa t t y  ac ids ,  ano the r  ou t come  va r iab le .  Fa t -so lub le  v i tam in  
(A ,  D ,  and  E )  concen t ra t ion  i s  a n  add i t iona l  e f f i cacy  endpo in t  and  w i l l  be  used  as  a  
labo ra to r y  ou t come  va r iab l e.  Se rum  p ro te in  ( to ta l  p ro te in ,  p rea lbum in ,  a lbum in ,  and  
t rans fe r r in )  concen t ra t ions  and  u r ina r y  leuko t r iene  concen t ra t ions  a re  add i t iona l  
endpo in t s  and  a l so  rep resen t  labo ra to r y  ou t come  va r iab les . 
 
Fo r  a l l  labo ra to r y  ou t come  va r iab les ,  mean  va lues  f rom  s amp les  ob ta ined  on  Day  -[ADDRESS_368841]  s co re  fo r  
we igh t  and  BM I  va lues  reco rded  on  Day s  30 ,  60 ,  and  90 .  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368842]  /  Independen t  E th i cs  Comm i t tee  
The  s i te  P I  w i l l  no t  beg in  the  resea r ch  s tudy  un t i l  the  Ins t i tu t iona l  Rev iew  Boa rd  ( IRB )  
o r  Independen t  E th i c s  Comm i t tee  ( IEC )  tha t  gove rns  the i r  pa r t i c ipa t ion  has  app roved  
the  p ro toco l  and  ICF .  The  IRB / IEC  w i l l  a l so  rev iew  and  app ro ve  a l l  adv e r t i semen t s ,  i f  
app l i cab le .  The  s i te  P I  w i l l  fo rwa rd  a  copy  o f  the  IRB / IEC  app rova l  documen t  to  
A l c res ta .  Any  p ro toco l  amendmen t s  mus t  a l so  be  app ro ved  in  w r i t ing  by  [CONTACT_36985] / IEC ,  
p r io r  to  imp lemen ta t ion  by  [CONTACT_941]  s i te  P I ,  ex cep t  whe re  neces sa r y  to  e l im ina te  an  
immed ia te  haza rd  to  s tudy  pa r t i c ipan t s .  
 
The  s i te  P I  w i l l  subm i t  a  p rog res s  repo r t  to  the  IRB / IEC  a t  in te r va l s  o f  one  yea r  o r  les s ,  
as  es tab l i shed  by  [CONTACT_301860] i t tees .  The  s i te  P I  w i l l  re ta in  a  copy  o f  th i s  re po r t  in  the  
Inves t iga to r ’s  S i te  F i le .  
 
 S tud y  Mon i to r ing  
The  mon i to r ing  p lan  and  aud i t ing  p rocedu res  de ve loped  o r  app ro ved  by  A l c res ta  w i l l  
be  fo l lowed  to  comp ly  w i th  cu r ren t  good  c l in i ca l  p rac t i ces  ( c GCP ) gu ide l i nes  and  
app l i cab le  regu la t ions .  The  s i te  mon i to r  w i l l  v i s i t  the  s i te  P I  and  s tudy  s i te  a t  pe r iod i c  
in te r va l s  and  ma in ta in  regu la r  s i te  commun i ca t ion .  The  s i te  P I  and  s tudy  s ta f f  i s  
expec ted  to  con tac t  the  s i te  mon i to r  d i rec t ly , rega rd ing  c l in i ca l  ques t ions  o r  c la r i f i ca t ion  
o f  p ro toco l  language .  
 
The  s i te  P I  w i l l  p repa re  and  ma in ta in  adequa te  and  ac cu ra te  sou r ce  documen t s  
des igned  to  reco rd  a l l  obse r va t ions  and  o the r  pe r t inen t  da ta  fo r  each  sub jec t .  The  
Inves t iga to r  w i l l  a l low  the  Sponso r ’s  rep resen ta t i ves ,  con t rac t  des ignees  and  
au tho r i zed  regu la to r y  au tho r i ty  inspec to r s  to  have  d i rec t  ac ces s  to  a l l  sou r ce  
documen t s  and  med i ca l  r eco rds  pe r ta in ing  to  the  sub jec t  p r io r  to  and  du r ing  the  
conduc t  pe r iod  o f  the  s tudy .  A c ces s  to  pa t ien t  reco rds  a f te r  pa r t i c ipa t ion  in  the  s tudy  i s  
comp l e te  may  be  requ i red  to  fo l low  reso lu t ion  o f  AE s  and  UADE s . 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  41  o f  47   
 Ons i te  Aud i ts  
Regu la to r y  au tho r i t ies ,  the  IRB / IEC , and  A l c res ta  (o r  A l c res ta ’s  con t rac t  vendo r )  may  
reques t  ac ces s  to  a l l  sou r ce  documen t s ,  eCRF s  and  o the r  s tudy  documen ta t ion  fo r  on -
s i te  aud i t  o r  inspec t ion .  The  s i te  P I  mus t  gua ran tee  d i rec t  ac ces s  to  these  documen t s .  
Med i ca l  reco rds  and  o the r  s tudy  documen t s  may  be  cop ied  du r ing  an  aud i t  o r  
inspec t ion , p rov ided  tha t  sub jec t  names  a re  ob l i te ra ted  on  the  cop ies  to  ensu re  
con f iden t ia l i ty .  
 
 S tudy  Dev i ce  A c coun tab i l i ty  
 
A l c res ta  o r  i t s  con t rac ted  vendo r  w i l l  a r range  fo r  sh ipmen t s  o f  the  inves t iga t iona l  
de v i ce  to  the  s tudy  s i tes  and  Pep tamen  1 .5  and  Impac t  Pep t ide  1 .5  to  the  sub jec t ’ s  
home .  An  inven to r y  o f  pac kage  con ten t s  w i l l  ac company  each  sh ipmen t  o f  c l in i ca l  
resea r ch  ma te r ia l s  and  anc i l la ry  supp l ies .  The  s tudy  coo rd ina to r  o r  des ign ee  mus t  
rece i ve  the  s tudy  ma te r ia l  de l i ve r y ,  rev iew  the  inven to r y ,  comp le te  the  reco rd  o f  rece ip t  
and  ensu re  c l in i ca l  resea r ch  ma te r ia l s  a re  p rope r l y  s to red  in  a  secu re ,  con t ro l led ,  
en v i ronmen ta l l y  app rop r ia te  loca t ion  and  sa fe l y  hand le d.  Cop ies  o f  a l l  sh ipp ing  
rece ip t s  and  d i spens ing  reco rds  fo r  the  ca r t r idges  mus t  be  re ta ined  a t  s i te  as  pa r t  o f  
requ i red  de v i ce  ac coun tab i l i ty .  
 
A c coun tab i l i ty  fo r  the  numbe r  o f  inves t iga t iona l  dev i ces  d i spensed  a t  the  s tudy  s i te  i s  
the  respons ib i l i ty  o f  the  s i te  P I  and  s tudy  s ta f f .  A c coun tab i l i ty  reco rds  mus t  ind i ca te  
de l i ve r y  to  the  s i te ,  a  reco rd  o f  in ven to r y ,  use  by  [CONTACT_301861] t  and  amoun t  re tu rned  to  
A l c res t a o r  des ignee .  S tudy  s ta f f  mus t  p ro v ide  the  s i te  mon i to r  w i th  reco rds  o f  the  
d i spos i t ion  o f  a l l  inves t iga t iona l  dev i ces .  The  s i te  mon i to r  w i l l  ac coun t  fo r  the  
d i spensa t ion  o f  c l in i ca l  resea r ch  s tudy  ma te r ia l s  a t  the  s i te  and  rev iew  Re l i zo rb  
ac coun tab i l i ty . A c coun tab i l i ty  o f  a l l  used  and  unopened  Re l i zo rb  pac kages  shou ld  
oc cu r  on  an  ongo ing  bas i s .  The  s i te  mon i to r  w i l l  a t temp t  to  reso l ve  any  d i s c repan c ies  
o f  c l in i ca l  resea r ch  ma te r ia l s  w i th  the  s tudy  coo rd ina to r  o r  des ignee .  On -s i te  d i sposa l  
o f  Re l i zo rb  w i l l  no t  be  pe rm i t ted  un les s  p rev ious ly  au tho r i zed  by  A l c res ta . 
 
 Pa t ien t  In fo rma t ion  and  In fo rmed  Consen t  
The  s i te  P I  w i l l  ob ta in  IRB / IEC  w r i t ten  app rova l  o f  the  ICF  ( inc lud ing  app rova l  o f  
rev i s ions )  to  be  p rov ided  to  the  pa t ien t s ,  inc lu s ive  o f  as sen t  fo r  m ino r s  7  to  17  yea r s  o f  
age .  P r io r  to  s tudy  en t r y ,  the  s i te  P I  o r  an  au tho r i zed  s ta f f  membe r  w i l l  in fo rm  pa t ien t s  
abou t  th e  na tu re  o f  the  s tudy .  Pa t ien t s  and /o r  pa ren t / ca reg i ve r s  w i l l  have  the  
oppo r tun i t y  to  inqu i re  abou t  de ta i l s  o f  the  s tudy  and  to  dec ide  on  pa r t i c ipa tion .  Pa t ien t s  
w i l l  be  ins t ruc ted  tha t  they  a re  f ree  to  w i thd raw  f rom  s tudy  pa r t i c ipa t ion  a t  any  t ime , 
w i thou t  pena l t y  o r  los s  o f  bene f i t s  to  wh i ch  they  a re  o the rw i se  en t i t led .   
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368843]  i t  was  g i ven  
to  the  pa t ien t  in  the  sou r ce  documen t s . 
 
 Pa t ien t  Con f iden t ia l i ty  
To  ma in ta in  pa t ien t  p r i vac y ,  a l l  eCRF s ,  dev i ce  ac coun tab i l i ty  reco rds ,  s tudy  repo r t s  
and  commun i ca t ions  w i l l  iden t i fy  the  pa t ien t  by  [INVESTIGATOR_2993] i t ia l s  and  as s igned  iden t i f i ca t ion  
numbe r .  The  pa t ien t ’s  con f iden t ia l i ty  w i l l  be  ma in ta ined  and  the i r  iden t i ty  w i l l  no t  be  
made  pub l i c ly  ava i lab le , to  the  ex ten t  pe rm i t ted  by  [CONTACT_97458] l i cab le  law s  and  reg u la t ions .   
  
Pa t ien t  da ta  s to red  on  a  compu te r  w i l l  be  hand led  in  ac co rdance  w i th  loc a l  da ta  
p ro tec t ion  law s .  Pa t ien t s  w i l l  be  in fo rmed  tha t  rep rese n ta t i ves  o f  the  Sponso r ,  IRB / IEC , 
o r  regu la to r y  au tho r i t ies  may  inspec t  the i r  med i ca l  reco rds  to  ve r i f y  in fo rma t ion  
co l lec ted  and  tha t  a l l  pe r sona l  in fo rma t ion  made  a va i lab le  fo r  inspec t ion  w i l l  be  
hand led  in  s t r i c tes t  con f idence  and  in  ac co rdan ce  w i th  loca l  da ta  p ro tec t ion  law s .  
 
 Inves t iga to r  Comp l iance  
The  s i te  P I  w i l l  no t  a l te r /mod i fy  th i s  c l in i ca l  s tudy  p ro t oco l  w i thou t  ob ta in ing  app rop r ia te  
p r io r  w r i t ten  ag reemen t  f rom  A l c res ta  and  the  IRB / IEC .  In  the  even t  o f  an  eme rgenc y ,  
the  s i te  P I  sha l l  imp lemen t  any  med i ca l  p rocedu res  deemed  app rop r ia te .  Howeve r ,  a l l  
such  p rocedu res  mus t  be  p romp t l y  repo r ted  to  the  Spo nso r  and  app rop r ia te l y  
documen ted  in  the  sou r ce  documen t s  fo r  th i s  s tudy .  
 
B y  s ig n ing  the  Inves t iga to r ’s  Ag reemen t  page  o f  th i s  p ro toco l , the  s i te  P I  con f i rm s  in  
w r i t ing  tha t  he / she  has  read ,  unde r s tands  and  w i l l  s t r i c t ly  adhe re  to  the  s tudy  p ro toco l , 
and  w i l l  conduc t  the  s tudy  in  ac co rdance  w i th  ICH  Gu ide l ines  fo r  GCP  and  app l i cab le  
regu la to r y  requ i remen t s .  B y  s ign ing  page  2 ,  the  s i te  P I  comm i t s  to  ensu r ing  tha t  a l l  s i te  
s ta f f  invo l ved  in  the  execu t ion  o f  th i s  s tudy  a re  qua l i f ied  and  p rope r ly  t ra ined  to  pe r fo rm  
the i r  as s igned  r es pons ib i l i t ies .  
 
9 .0  STUDY  COMPLET ION  PRO CEDURES  
 Comp le t ion  o f  S tudy  
A t  the  end  o f  the  s tudy ,  A l c res ta  w i l l  p rov ide  w r i t ten  documen ta t ion  to  a l l  inves t iga t i ve  
s i tes  and  cen t ra l  IRB s  tha t  the  s tudy  i s  c losed .  The  s i te  mon i to r  w i l l  conduc t  c lose -ou t  
v i s i t s and  ensu re  tha t  IRB / IEC  a re  no t i f ied  o f  s tudy  c losu re .  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  [ADDRESS_368844] ing  to  ICH -GCP , and  app l i cab le  
regu la to r y  requ i remen t s .  Reco rds  w i l l  be  re ta ined  and  p rese r ved  un t i l :  
• At  leas t  two  yea r s  a f te r  the  las t  ma r ke t ing  app l i ca t ion  app rova l  o r  A l c res ta  has  
d i s con t inued  resea r ch  w i th  Re l i zo rb  o r  
• A t  leas t  two  yea r s  s ince  the  fo rma l  d i s con t inua t ion  o f  c l in i ca l  deve lopmen t  o f  
Re l i zo rb . 
 
These  documen t s  w i l l  be  re ta ined  fo r  a  longe r  pe r iod  i f  requ i red  by  [CONTACT_301862] l i cab le  
regu la to r y  requ i remen t s  o r  the  hosp i ta l ,  ins t i tu t ion  o r  p r i va te  p rac t i ce  in  wh i ch  the  s t udy  
i s  be ing  conduc ted .  A t  the  end  o f  the  above  pe r iods ,  the  s i te  P I  w i l l  no t i fy  A l c res ta  in  
w r i t ing  o f  the  in ten t  to  des t roy  s tudy  reco rds .  A lc res ta  sha l l  have  30  day s  to  respond  to  
the  s i te  P I ’s  no t i f i ca t ion  and  may  as sume  paymen t  fo r  con t inued  reco rd  re ten t ion .  
 
Cus tody  o f  the  reco rds  may  be  t rans fe r red  to  ano the r  respons ib le  s i te  P I ,  deeme d  
ac cep tab le  to  A l c res ta ,  who  ag rees  to  ab ide  by  [CONTACT_301863] t ion  po l i c ies .  W r i t ten  no t i ce  o f  
t rans fe r  mus t  be  subm i t ted  to  the  Sponso r  and  to  the  s i te ’s  IRB / IEC .  The  s i te  P I  mus t  
con tac t  A l c res ta  p r io r  to  d i spos ing  o f  any  s tudy  reco rds .  
 
 Commun ica t ion  o f  S tu dy  Resu l ts  
A l l  in fo rma t ion  rega rd ing  use  o f  Re l i zo rb ,  the  p ro toco l  and  a l l  o the r  s tudy  ma te r ia l s  a re  
p r i v i leged  and  con f iden t ia l  in fo rma t ion .  The  s i te  P I  ag rees  to  use  th i s  in fo rma t ion  to  
execu te  the  s tudy  and  w i l l  no t  use  i t  fo r  o the r  pu rposes , w i thou t  co nsen t  f rom  A l c res ta . 
 
I t  i s  an t i c ipa ted  tha t  the  resu l t s  o f  th i s  s tudy  w i l l  be  p resen ted  a t  med i ca l  con fe rence s  
and  w i l l  be  ava i lab le  in  s c ien t i f i c  pub l i ca t ions  o r  med i ca l  jou rna l s. 
 
Pub l i ca t ion  by  [CONTACT_941]  s i te  o f  any  da ta  f rom  th i s  s tudy  i s  s t r i c t ly  p roh ib i ted .  Any  ex cep t ions  
mus t  be  ca r r ied  ou t  in  ac co rdance  w i th  the  C l in ica l  T r ia l  Ag reemen t .  
  
 E th ics  
Th i s  s tudy  w i l l  be  conduc ted  in  ac co rdance  w i th  app l i cab le  s tanda rds  o f  GCP  (21  Code  
o f  Fede ra l  Regu la t ions  P a r t  812 ) ,  in  ag reemen t  w i th  the  D ec la ra t io n  o f  He l s ink i  and  in  
keep ing  w i th  fede ra l  and  loca l  regu la t ions .  The  IRB / IEC  w i l l  rev iew  a l l  app rop r ia te  
s tudy  documen ta t ion  to  sa fegua rd  the  r igh t s ,  sa fe t y  and  we l l  be ing  o f  pa t ien t s .  Th i s  
s tudy  w i l l  on ly  be  conduc ted  a t  s i tes  whe re  IRB / IEC  app ro va l s  have  been  ob ta ined .  
The  s i te  P I  w i l l  be  tho rough l y  fam i l ia r  w i th  the  p rope r  use  o f  Re l i zo rb  as  des c r ibed  in  
the  p ro toco l , and  the  co r respond ing  Inves t iga to r ’s  B rochu re .  
 
  
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  44  o f  47  10 .0  REFERENCES  
1 .  A l -Kaade ,  S ,  et  a l .  E xoc r ine  panc rea t i c  insu f f ic ienc y .  eMed i c ine  Meds cape . 
[On l ine ]  Jan  29 ,  2013 .  h t tp : / /emed i c ine .meds cape . com /a r t i c le  
 
2 .  Zopp i  G ,  e t  a l .  E x oc r ine  panc reas  func t ion  in  p re ma tu re  and  fu l l  te rm  neona tes .  
Ped ia t r i c  Resea r ch  1972 ;  6 : 880 -886  
 
3 .  Figa re l la  C ,  e t  a l .  Congen ital  panc rea t i c  l ipase  de f i c ienc y .  The  Jou rna l  o f  
Ped ia t r i c s  1980 ;  96 (3 ) :412 -416  
 
4 .  h t tp : / /www .n im .n ih .gov /med l inep lus /panc rea t i c cance r .h tm l  
 
5 .  F l e i th  M ,  e t  a l .  D ie ta ry  PUFA  fo r  p re te rm  and  te rm  in fan t s :  rev iew  o f  c l in i ca l  
s tud ies .  C r i t i ca l  Rev iew s  in  Food  S c ience  and  Nu t r i t ion  2005 ;  45 (3 ) :205 -229  
 
6 .  Guy ton  A ,  Ha l l  JE .  Tex tbook  o f  med i ca l  phy s io logy .  Ed i t ion  11 ,  s . l . :  E l sev ie r ,  
2006 ;  808 -819  
 
7 .  Rus se l l ,  FD ,  e t  a l .  D i s t ingu i sh ing  hea l th  bene f i t s  o f  e i cosapen taeno i c  and  
docosahexaeno i c .  Ma r ine  D rugs  2012 ;  10 :2535 -2559  
 
8 .  M-P .  S t -Onge ,  P . J .H .  Jones  (2003 ) .  "G rea te r  r i se  in  fa t  ox ida t ion  w i th  med ium -
cha in  t r igy l ce r ide  consump t ion  re la t i ve  to  long -cha in  t r ig ly ce r ide  i s  as soc ia ted  
w i th  lowe r  in i t ia l  body  we igh t  and  g rea te r  los s  o f  subcu taneous  ad ipose  t i s sue " .  
In te rna t iona l  Jou rna l  o f  Obes i t y  27  (12 ) :  1565 -1571  
 
9 .  Kidd ,  PM .  Omega -3  DHA  and  EPA  fo r  cogn i t ion ,  beha v io r  and  mood :  c l in i ca l  
f ind ings  and  s t ruc tu ra l -func t iona l  syne rg ies  w i th  ce l l  memb rane  phospho l ip ids .  
A l te rna t i ve  Med  R ev iew  2007 ;  12 : 3 
 
10 .  K ieco l t -G lase r  JK .  S t res s ,  Food ,  and  In f lamma t ion :  P s y choneu ro immuno logy  
and  Nu t r i t ion  a t  the  Cu t t ing  Edge .  B io l  P sy ch ia t r y .  2014  Dec  8 .  p i i :  S0006 -
3223 (14 )  [ZIP_CODE] -4 
 
11 .  O l i ve i ra  G .  Se rum  phospho l ip id  fa t ty  ac id  p ro f i le  and  d ie ta r y  in take  in  an  adu l t  
Med i te r ranean  popu la t ion  w i th  cy s t i c  f ib ros i s .  B r i t i sh  Jou rn a l  o f  Nu t r i t ion  (2006 ) ,  
96 ,  343 -349  
 
12 .  L loyd -S t i l l  JD  e t  a l .  B ioava i lab i l i ty  and  sa fe ty  o f  a  h igh  dose  o f  docosahexaeno i c  
ac id  t r iacyg ly ce ro l  o f  a lga l  o r ig in  in  cy s t i c  f ib ros i s  pa t ien t s :  a  random i zed  
con t ro l led  s tudy .  Nu t r i t ion  22  (2006 )  36 -46  
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
Page  45  o f  47  13 .  Ka l i v ianak i  M  e t  a l .  Fa t  ma labso rp t ion  in  cy s t i c  f ib ros i s  pa t ien t s  rece i v ing  
enz yme  rep lacemen t  the rapy  i s  due  to  impa i red  in tes t ina l  up take  o f  long -cha in  
fa t ty  ac ids .  Am  J  C l in  Nu t r  1999 ;  69 :127 -34  
 
14 .  A l c res ta  abs t rac t .  Nove l  immob i l i zed  l ipase  de v i ce  (EF IC™ )  enhances  the  
nu t r i t iona l  bene f i t s  o f  en te ra l  feed ing  and  p ro v ides  g rea te r  f lex ib i l i ty  fo r  sho r te r  
du ra t ion  feed ings  and  reduced  vo lumes .  Abs t rac t  fo r  ECSF  2015  ac cep ted  as  
o ra l  p resen ta t ion  
 
15 .  A l c res ta  repo r t  #000045 2-03 . 24h  pha rmacodynam i c  p ro f i le  o f  to ta l  fa t  and  fa t ty  
ac id  a f te r  s ing le  G -tube  feed ing  w i th  EF IC  p re -hyd ro ly zed  Pep tamen  AF ,  BF -03  
s tudy  
 
16 .  A l c res ta  repo r t  #0000450 -04 . Long -te rm ,  12  day s  e f f i c ienc y  s tudy  in  EP I  p igs  
fed  w i th  G -tube  EF IC  p re -hyd ro ly zed  Pep tamen  AF ,  BF -03  s tudy  
 
17 .  A l c res ta  repo r t  #0000 164 -02.  Tes t ing  the  e f f i cacy  o f  m i c rob ia l  l ipase  fo r  
d iges t ion  o f  long -cha in  po l yunsa tu ra ted  fa t ty  ac id  (LCPUFA )  in  the  in fan t  
fo rmu la  in  young  p igs  w i th  to ta l  panc rea t i c  insu f f i c iency ,  BF -02  s tudy  
 
18 .  A l c res ta  repo r t  #0000134 -01 . H i s topa tho logy  eva lua t ion  to  A l c res ta  Inc . s tudy    
numbe r  BF -02  2012  (Tes t ing  the  e f f i cacy  o f  immob i l i sed  Rh i zopus  o r y zae  
l ipases  fo r  d iges t ion  o f  long  cha in  po lyunsa tu ra ted  fa t ty  ac id  (LCPUFA )  in  the  
in fan t  fo rmu la  fed  young  p igs  w i th  to ta l  panc rea t i c  in su f f i c ienc y  BF -02  s tudy  
 
19 .  A l c res ta  repo r t  #0000293 -01 .  A  Random i zed ,  Doub le  B l ind  C ros sove r  S tudy  in  
Hea l thy  Adu l t  Sub jec t s  to  E va lua te  Sa fe t y ,  To le rab i l i ty ,  and  Ra te  and  E x ten t  o f  
Abso rp t ion  o f  Long -Cha in  Po l yunsa tu ra ted  Fa t t y  A c ids  (LCPUFA s )  f rom  a  
Nu t r i t iona l  D r ink  P re -hyd ro ly zed  by  E xposu re  to  ALCT -460  
 
20 .  A l c res ta  repo r t  #0000749 -01 .  Cl in i ca l  Study  Repo r t :  P ro toco l  [ADDRESS_368845] -460  in  Panc rea t i c  Insu f f i c ien t  Sub jec t s  
 
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
 
 Page  46  o f  47  11 .0  APPEND ICES  
 Pep tamen ® 1 .5  Nu t r i t ion  In fo rma t ion  - Un f lavo red  (Nes t le  Hea l th  
Sc ience )  
 
 One  bo t t le  equa ls  250  mL  ( 1Ca r ton )  
Amoun t  Pe r  Se rv ing  Un i t  Amou n t  Amoun t  pe r  Se rv ing  Un i t  Amoun t   
Ca lo r ies  Kc a l  375  To ta l  Fa t  *  g 14  
Sod ium  mg  (mEq )   255  
(11 .1 )  Po ta s s ium  mg  (mEq )  465  (12 )  
To ta l  Ca rboh yd ra te  G  46  P ro te in  g 17  
V i tam in  A * *  IU  1615  V i tam in  C  mg  128  
Ca l c ium  Mg  250  I ron  mg  6 .75  
V i tam in  D  IU  200  V i tam in  E IU  11 .3  
V i tam in  K  M cg  30  Th iam in  mg  0 .75  
R ibo f lav in  Mg  0 .9  N ia c in  mg  10 .5  
V i tam in  B 6 Mg  1 .5  Fo l i c  Ac id  mcg  200  
V i tam in  B 12  M cg  3 B io t in  mcg  150  
Pan to then i c  Ac id  Mg  5 .25  Phospho ru s  mg  250  
Iod ine  M cg  56  Magnes ium  mg  100  
Z in c  Mg  9 Se len ium  mcg  19  
Coppe r  Mg  0 .75  Manganese  mg  1 
Ch rom ium  M cg  15  Mo l ybdenum  mcg  45  
Ch lo r ide  mg  (mEq )  435  (12 .3 )  L-Ca rn i t ine  mg  37 .5  
Tau r ine  Mg  37 .5  Cho l ine  mg  170  
Wa te r  mL  193     
*  MCT  p rov ide s  10  g /250  mL  
* *  In c ludes  37 %  o f  v i tam in  A  a c t i v i ty  f rom  be ta -ca ro tene  
 
 
Ing red ien ts  o f  Pep tamen ® 1 .5  (Un f lavo red ) :  
Wa te r ,  Ma l todex t r in ,  En z yma t i ca l l y  Hyd ro l y zed  Whe y  P ro te in  ( f rom  M i l k ) ,  Med ium  Cha in  T r ig l y ce r ide s  ( f rom  
Co conu t  and /o r  Pa lm  Ke rne l  O i l ) ,  and  le s s  than  2%  o f  Co rn s ta r ch ,  Soybean  O i l ,  Soy  Le c i th in ,  Magne s ium  
Ch lo r ide ,  Sod ium  A s co rba te ,  Sod ium  Pho spha te ,  Ca l c ium  Pho spha te ,  Gua r  Gum ,  Ca l c ium  C i t ra te ,  Cho l ine  
Ch lo r ide ,  Po ta s s ium  Ch lo r ide ,  Sa l t ,  Sod ium  C i t ra te ,  Tau r ine ,  L -Ca rn i t ine ,  Magne s ium  Ox ide ,  A lpha -To cophe ry l  
A ce ta te ,  Z in c  Su l fa te ,  Fe r rou s  Su l fa te ,  N ia c inam ide ,  Ca l c ium  Pan to thena te ,  V i tam in  A  Pa lm i ta te ,  Po ta s s ium  
C i t ra te ,  Mangane se  Su l fa te ,  Py r idox ine  Hyd ro ch lo r ide ,  V i tam in  D 3,  Coppe r  Su l fa te ,  Th iam ine  Monon i t ra te ,  
R ibo f lav in ,  Be ta  Ca ro ten e ,  Fo l i c  A c id ,  B io t in ,  C i t r i c  A c id ,  Po ta s s ium  Iod ide ,  Ch rom ium  Ch lo r ide ,  Sod ium  
Se lena te ,  Sod ium  Mo l ybda te ,  Ph y tonad ione ,  V i tam in  B 12 . 
 
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
 
 Page  47  o f  47   Impac t  Pep t ide  1 .5  Nu t r i t ion  In fo rma t ion  - Un f lavo red  (Nes t lé  Hea l thca re  
Nu t r i t ion )   
 
 One  bo t t le  equa l s  250  mL  (1  Ca r ton  i s  8 .45  oun ces )  
Amoun t  Pe r  Se rv ing  Un i t  Amou n t  Amoun t  pe r  Se rv ing  Un i t  Amoun t   
Ca lo r ies  ca l  375  To ta l  Fa t  *  g [ADDRESS_368846] /LCT  ra t io  50 :50  
DHA +EPA  g 1 .225  Sod ium  mg  292  
Po ta s s ium  mg  468  Ca rboh yd ra te  g 35  
P ro te in  g 23 .5  V i tam in  A  IU  3750  
V i tam in  C   mg  250  Ca l c ium  mg  250  
I ron  mg  4 .5  V i tam in  D  IU  200  
V i tam in  E  IU  25  V i tam in  K  mcg  18 .7  
Th iam ine  (V i tam in  B 1) mg  0 .75  R ibo f lav in  (V i tam in  B 2) mg  0 .6  
N ia c in  mg  7 V i tam in  B6  mg  1 
V i tam in  B12  mcg  2 B io t in  mcg  100  
Pan to then i c  Ac id  mg  3 .5  Phospho ru s  mg  250  
Iod ine  mcg  40  Magnes ium  mg  105  
Z in c  mg  9 Se len ium  mcg  25  
Coppe r  mg  0 .75  Manganese  mg  1 
Ch rom ium  mcg  35  Mo l ybdenum  mcg  55  
Ch lo r ide  mg  435  Cho l ine  mg  138  
Fo l i c  Ac id  mcg  135  L-Ca rn i t ine  mg  37 .5  
Tau r ine  mg  70   
 
 
Ing red ien ts  o f  Impac t ® Pep t ide  1 .5  (Un f lavo red ) :  
Wa te r ,  Ma l tode x t r in ,  En zyma t ica l ly  Hyd ro ly zed  Whe y  P ro te in  ( f rom  M i lk ) ,  Med ium  Cha in  
T r ig ly ce r ide s  ( f rom  Co conu t  and /o r  Pa lm  Ke rne l  O i l ) ,  con ta in s  le s s  than  2%  o f  L -A rg in ine  
Co rn s ta rch ,  Re f ined  F ish  O i l  (An cho vy ,  Sa rd ine ) ,  Soybean  O i l ,  C i t r ic  A c id ,  Ca lc ium  C i t ra te ,  
Yea s t  E x t ra c t ,  Magne s ium  Ch lo r ide ,  Po ta s s ium  Phospha te ,  A s co rb ic  A c id ,  Sa l t ,  Hd ro xy la ted  
Soy  Le c i th in ,  Sod ium  C i t ra te ,  Cho l ine  Ch lo r ide ,  Gua r  Gum ,  Xan than  Gum ,  Po ta s s ium  
C i t ra te ,  Tau r ine ,  Magne s ium  O x ide ,  Sod ium  A s co rba te ,  A lpha -To cophe ry l  A ce ta t e ,  
L-Ca rn i t ine ,  Z in c  Su l fa te ,  Fe r rou s  Su l fa te ,  N ia c inam ide ,  V i tam in  A  Pa lm i ta te ,  Ca lc ium  
Pan to thena te ,  Mangane se  Su l fa te ,  V i tam in  D 3,  Coppe r  Su l fa te ,  Py r ido x ine  Hyd ro ch lo r ide ,  
Be ta  Ca ro tene ,  Th iam ine  Monon i t ra te ,  R ibo f la v in ,  Fo l ic  A c id ,  Ch rom ium  Ch lo r ide ,  B io t in ,  
Sod ium  Mo lybda te ,  Po ta s s ium  Iod ide ,  Sod ium  Se lena te ,  Phy tonad ione  and  V i tam in  B 12 .
A l c res ta  Pha rma ceu t i ca l s ,  In c .  Do cumen t  Numbe r :  0000498  VER .  02  
Do cumen t  S ta tu s :  App roved /E f fec t ive  E f fe c t i ve  Da te :  09 -Ma r -2016  
 
T i t le :   Abso rp t ion  and  Sa fe ty  w i th  Sus ta ined  Use  o f  Re l i zo rb ™ Eva lua t ion  (Assu re )  S tudy  in  
Pa t ien ts  W i th  Cys t ic  F ib ros is  Rece iv ing  En te ra l  Feed in g 
 
Con f iden t ia l  In fo rma t ion  - Do  No t  Rep rodu ce  W i thou t  Au tho r i za t ion  
  